<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10156733</article-id><article-id pub-id-type="pmid">37137912</article-id><article-id pub-id-type="publisher-id">38218</article-id><article-id pub-id-type="doi">10.1038/s41467-023-38218-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic>N</italic>-Formimidoylation/-iminoacetylation modification in aminoglycosides requires FAD-dependent and ligand-protein NOS bridge dual chemistry</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yung-Lin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Chin-Yuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5735-4606</contrib-id><name><surname>Hsu</surname><given-names>Ning-Shian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lo</surname><given-names>I-Wen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Kuan-Hung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chun-Liang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Chi-Fon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhe-Chong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3144-3985</contrib-id><name><surname>Ogasawara</surname><given-names>Yasushi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3406-7970</contrib-id><name><surname>Dairi</surname><given-names>Tohru</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maruyama</surname><given-names>Chitose</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5117-5116</contrib-id><name><surname>Hamano</surname><given-names>Yoshimitsu</given-names></name><address><email>hamano@fpu.ac.jp</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9739-9761</contrib-id><name><surname>Li</surname><given-names>Tsung-Lin</given-names></name><address><email>tlli@gate.sinica.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.28665.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2287 1366</institution-id><institution>Genomics Research Center, </institution><institution>Academia Sinica, </institution></institution-wrap>Taipei, 11529 Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.260539.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2059 7017</institution-id><institution>Department of Biology Science and Technology, </institution><institution>National Yang Ming Chiao Tung University, </institution></institution-wrap>Hsinchu, 30010 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.39158.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2173 7691</institution-id><institution>Graduate School of Engineering, </institution><institution>Hokkaido University, Kita-ku, </institution></institution-wrap>Sapporo, Hokkaido 060-8628 Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411756.0</institution-id><institution>Graduate School of Bioscience and Biotechnology, </institution><institution>Fukui Prefectural University, Eiheiji-cho, </institution></institution-wrap>Fukui, 910-1195 Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.411756.0</institution-id><institution>Fukui Bioincubation Center (FBIC), </institution><institution>Fukui Prefectural University, Eiheiji-cho, </institution></institution-wrap>Fukui, 910-1195 Japan </aff><aff id="Aff6"><label>6</label>Biotechnology Center, National Chung Hsing University, Taichung City, 402 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><elocation-id>2528</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Oxidized cysteine residues are highly reactive and can form functional covalent conjugates, of which the allosteric redox switch formed by the lysine-cysteine NOS bridge is an example. Here, we report a noncanonical FAD-dependent enzyme Orf1 that adds a glycine-derived <italic>N</italic>-formimidoyl group to glycinothricin to form the antibiotic BD-12. X-ray crystallography was used to investigate this complex enzymatic process, which showed Orf1 has two substrate-binding sites that sit 13.5&#x02009;&#x000c5; apart unlike canonical FAD-dependent oxidoreductases. One site could accommodate glycine and the other glycinothricin or glycylthricin. Moreover, an intermediate-enzyme adduct with a NOS-covalent linkage was observed in the later site, where it acts as a two-scissile-bond linkage facilitating nucleophilic addition and cofactor-free decarboxylation. The chain length of nucleophilic acceptors vies with bond cleavage sites at either N&#x02013;O or O&#x02013;S accounting for <italic>N</italic>-formimidoylation or <italic>N</italic>-iminoacetylation. The resultant product is no longer sensitive to aminoglycoside-modifying enzymes, a strategy that antibiotic-producing species employ to counter drug resistance in competing species.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">A biosynthetic enzyme that mediates ligand-protein NOS chemistry allowing addition and decarboxylation alongside noncanonical FAD-dependent reactions to implement the N-formimidoylation/-iminoacetylation modification in aminoglycosides was uncovered.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Structural biology</kwd><kwd>Biochemistry</kwd><kwd>Biocatalysis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004663</institution-id><institution>Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan)</institution></institution-wrap></funding-source><award-id>MOST-108-2113-M-001-021-MY3</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Tsung-Lin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001869</institution-id><institution>Academia Sinica</institution></institution-wrap></funding-source><award-id>AS-KPQ-109-BioMed</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Tsung-Lin</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">ST-F the first known congener out of the streptothricins (STs) family was isolated from the culture of <italic>S. lavendulae</italic> in 1943 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Its chemical framework is composed of an unusual aminosugar, carbamoylated <italic>D</italic>-gulosamine, to which two nonproteinogenic amino acids, streptolidine (a bicyclic streptolidine lactam) and L-&#x003b2;-lysine (&#x003b2;-Lys), are adorned respectively at the anomeric carbon and C2-amine. Analogs with various lengths of &#x003b2;-Lys oligopeptides such as ST-D and ST-E (with oligo(&#x003b2;-Lys)<sub>3</sub> and oligo(&#x003b2;-Lys)<sub>2</sub>, respectively.), which exhibit relatively higher antibacterial activity<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Other ST congeners with structural nuances exist, such as BD-12 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>2</bold>) which has an unusual <italic>N</italic>-formimidoylglycine in place of the &#x003b2;-Lys oligopeptide<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup>, and glycinothricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>1</bold>), which is similar to BD-12 but lacks the <italic>N</italic>-formimidoyl group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>)<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. STs are broad-spectrum antimicrobials that inhibit protein synthesis in bacteria, fungi, and insects, but not phytogrowth<sup><xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref></sup>. However, the severe cytotoxicity of STs, such as nephrotoxicity, limits their clinical use<sup><xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref></sup>. To reduce STs&#x02019; toxicity in eukaryotes, substantial efforts with organic chemistry-based strategies were made but remained in vain<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.<fig id="Fig1"><label>Fig. 1</label><caption><title>Chemical structures of STs and ST-related antibiotics.</title><p><bold>a</bold> The gene product of <italic>orf1</italic> encoded in the BD-12 producing strain is able to catalyze glycinothricin to BD-12. Other than glycinothricin, glycylthricin, 3-aminopropionylthricin, 4-aminobutylthricin and ST-F can serve as substrates of Orf1 to bring on <italic>N</italic>-formimidoylated or <italic>N</italic>-iminoacetylated corresponding products. <bold>b</bold> The <italic>N</italic>-formimidoylation or <italic>N</italic>-iminoacetatylation was presumed to follow multiple steps of reactions in one single reaction site as does a typical FAD-dependent enzyme. <bold>c</bold> The proposed mechanisms of <italic>N</italic>-formimidoylation or <italic>N</italic>-iminoacetylation catalyzed by Orf1 that recruits a FAD prosthetic group and an NOS protein-ligand covalent modification to enable multiple reactions to take place at two separate but adjacent reaction chambers. Four-membered peroxide and three-membered oxaziridine that may respectively react with oxidized and non-oxidized cysteine to form the NOS linkage, however, were not detected in any circumstances. In the presence of proper acceptors (e.g., <bold>1</bold> or <bold>4</bold>), products <bold>2,</bold>
<bold>5</bold> with the <italic>N</italic>-formimidoyl modification are formed by Orf1, in which sulfenic C281 is recyclable (reactivated only once). R&#x02019;HN&#x02019; colored blue is glycylthricin analogs (e.g., compound <bold>7</bold>) with various aliphatic side chains in length leading to <italic>N</italic>-iminoacetyl modification. In this circumstance, apart from hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) sulfenic C281 can be regenerated by water as determined by isotope labeling experiments using H<sub>2</sub><sup>18</sup>O highlighted red (see Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>).</p></caption><graphic xlink:href="41467_2023_38218_Fig1_HTML" id="d32e537"/></fig></p><p id="Par4">The biosynthesis of STs from various <italic>Streptomyces</italic> species has been extensively elucidated<sup><xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup>. Of them, the biosynthesis of BD-12 (accession no. LC122485) differs from others as it recruits a Fem-like enzyme to install a glycine at the C2-amine of streptothrisamine in a tRNA-dependent manner, resulting in the production of glycinothricin<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. Orf1, which encodes a <italic>N</italic>-formimidoyl fortimicin A synthase-like enzyme, has been proposed to convert glycinothricin to BD-12. In silico analysis indicates that Orf1 is a flavoprotein oxidoreductase (monooxygenase, FPMO or oxidase, FPOX). FPMO or PFOX are classified into three main categories (I-III), which are further subdivided into nine subgroups (A-I)<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. Orf1 belongs to category III since its own substrate reduces flavin as opposed to those requiring an external NAD(P)H (category I; the one-component) or a NAD(P)H-dependent flavin reductase (category II; the two-component)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. The <italic>N</italic>-formimidoyl group in <italic>N</italic>-formimidoyl fortimicin A originates from glycine through multiple reactions, including glycine oxidation, amine addition, second oxidation, and decarboxylation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). The enzyme (Fsm14) that catalyzes this modification is characterized as a FAD-dependent oxidase (FPOX) because two stoichiometric quantities of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) are produced at the expense of one equivalent of glycine<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. However, this conclusion conflicts with the current understanding of FAD-dependent oxidative decarboxylation, where H<sub>2</sub>O<sub>2</sub> commonly engages with a presumed imino product of the first-half reaction. Furthermore, it remains unclear how multiple reactions are hierarchically executed in a single enzyme (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>)<sup><xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref></sup>.</p><p id="Par5">Bacterial resistance to aminoglycoside antibiotics that inhibit protein biogenesis can occur by decreasing antibiotic uptake/accumulation (e.g. efflux pumps), altering 16&#x02009;S rRNA, other ribosomal proteins, or modifying chemical structures of antibiotics per se (e.g. aminoglycoside acetyltransferases, AACs)<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. The inactivation of STs has been ascribed largely to chemical modification of the oligo(&#x003b2;-Lys) sidechain by &#x003b2;-<italic>N</italic>-acetylation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>) as manifested in the ST producers <italic>S. lavendulae</italic><sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>, <italic>S. rochei</italic><sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, and <italic>S. noursei</italic><sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, where a universal gene encoding an <italic>N</italic>-acetyltransferase (NAT) is applied to the acetylation modification at the &#x003b2;-amine group of the &#x003b2;-Lys pharmacophore. Whether the <italic>N</italic>-formimidoyl modification is immune or succumbs to <italic>N</italic>-acetylation by ST-NAT alike (e.g. SttE from <italic>S. lavendulae</italic>) is still an unanswered issue. An encouraging example is that FDA-approved &#x003b2;-lactam antibiotic imipenem that is <italic>N</italic>-formimidoylated thienamycin<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, demonstrating superior efficacy to the latter for both drug resistance and stability. Similarly, <italic>N</italic>-formimidoyl fortimicin A (dactimicin) is insusceptible to AAC3 as well as has lower nephrotoxicity<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>.</p><p id="Par6">Here we report that Orf1 is a FAD-dependent enzyme encompassing two separate reaction centers one catalyzing formation of a reactive aldoxime-like intermediate and the other catalyzing a <italic>N</italic>-formimidoyl substitution reaction. Together, these reactions make Orf1 an noncanonical FAD-dependent monooxygenase (functionally Orf1 should be termed as <italic>N</italic>-formimidyol/iminoacetyl synthase) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). Most amazingly, the enzyme evolves an unprecedented N&#x02013;O&#x02013;S enzyme-substrate linkage rod mechanism to mediate nucleophilic addition and FAD-peroxide-independent decarboxylation reactions. The <italic>N</italic>-formimidoyl modification is a result of molecular evolution enriching the structural landscape of STs, intrinsically diversifying the types of molecules and leveraging bacterial drug-resistance.</p></sec><sec id="Sec2" sec-type="results"><title>Results and discussion</title><sec id="Sec3"><title>In vitro/in vivo characterization of Orf1</title><p id="Par7">BD-12 features an unusual <italic>N</italic>-formimidoyl functional group at the terminus of its glycyl sidechain in contrast to a typical ST that displays primary amine groups at its oligo(&#x003b2;-Lys)<sub>n</sub> sidechain. Previously, we identified the BD-12 biosynthetic gene cluster (BGC) in <italic>Streptomyces luteocolor</italic> NBRC 13826 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>) and heterologous host strains (<italic>Streptomyces lividans</italic> TK23 and <italic>Streptomyces avermitilis</italic> SUKA17) expressing the BGC that produces BD-12<sup>(ref24)</sup>. It has been known that the glycyl moiety is transferred to streptothrisamine by a Fem-like enzyme (<italic>orf11</italic>) at the expense of one molecule of Gly-tRNA to form <bold>1</bold> prior to the addition of the <italic>N</italic>-formimidoyl group<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The <italic>orf</italic>1 gene that encodes a <italic>N</italic>-formimidoyl fortimicin A synthase-like enzyme in the BD-12 BGC was thought to commit the formimidoylation reaction in the presence of glycine<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. To confirm this hypothesis, the <italic>orf1</italic> gene was inactivated by an in-frame deletion and introduced into <italic>S. avermitilis</italic> SUKA17. The resulting transformant, SUKA17-BD-12-&#x00394;orf1, was cultured and analyzed by high-performance liquid chromatography and high-resolution electrospray ionization mass spectrometry (HPLC-HR-ESI-MS). Compared to TK23-BD-12, carrying the BD-12 biosynthetic gene cluster (wild type), the deletion of <italic>orf1</italic> abolished the biosynthesis of BD-12 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1b</xref>). In a further HPLC-HR-ESI-MS analysis of the culture broth, the TK23-BD-12-&#x00394;orf1 strain was shown to produce a compound (m/z 460.215 [M&#x02009;+&#x02009;H]<sup>+</sup>) rather than BD-12 (m/z 487.226 [M&#x02009;+&#x02009;H]<sup>+</sup>). The mass decrease by 27&#x02009;Da was in good agreement with the fact that the <italic>orf1</italic> gene homologous to an <italic>N</italic>-formimidoyl synthase gene was inactivated; the &#x00394;27 Da compound seemed to be <bold>1</bold>. To confirm the chemical structure of <bold>1</bold>, it was purified from the culture broth, and NMR analysis clarified that compound <bold>1</bold> is indeed glycinothricin (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>; Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). Moreover, these results strongly suggested that <bold>1</bold> was the biosynthetic precursor of BD-12 and a substrate of the <italic>orf1</italic> gene product (<italic>N</italic>-formimidoyl synthase).</p><p id="Par8">Two glycylation reactions executed by two different types of enzymes in a row are rare if any. The <italic>N</italic>-formimidoyl modification is peculiarly intriguing as a barrage of reactions apparently goes with the territory starting with free glycine oxidation and ending on a bulky recipient with a unique <italic>N</italic>-formimidoyl substitution. To explore this fascinating issue, recombinant Orf1 expressed in <italic>E. coli</italic> displays yellow tetrameric proteins in the solution while eluting out of gel filtration chromatography (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3a, b</xref>). The yellow color indicates each polypeptide chain harbors a flavin prosthetic group as opposed to the formylglycine-generating enzyme (FGE), which is a copper I dependent enzyme<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. This yellow cofactor was determined to be flavin adenine dinucleotide (FAD) by subjecting the supernatant of denatured proteins to LC-MS analysis (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3c</xref>). Biochemical assays were performed in parallel, wherein reaction mixtures containing glycine and a chemically synthesized glycylthricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>4</bold>) instead of <bold>1</bold> were quenched in due course and subjected to LC analysis. When compared with the control (addition with denatured Orf1), a new peak that emerged on the LC trace matched with the synthetic standard in the same retention time, mass unit and fragmentation pattern, suggesting that Orf1 is a flavin-dependent enzyme capable of <italic>N</italic>-formimidoylating the terminal glycyl sidechain of glycylthricin to <bold>5</bold> in the presence of glycine. To confirm that the <italic>N</italic>-formimidoyl moiety is derived from an intact molecule of glycine, we performed Orf1-mediated reactions with the addition of glycine, (<sup>15</sup>N)-glycine, (1&#x02212;<sup>13</sup>C)-glycine, (2&#x02212;<sup>13</sup>C)-glycine, (2&#x02212;<sup>13</sup>C &#x02212;<sup>15</sup>N)-glycine, or (1,2&#x02212;<sup>13</sup>C<sub>2</sub>&#x02212;<sup>15</sup>N)-glycine alongside <bold>4</bold>. LC-MS spectra clearly demonstrate that the <italic>N</italic>-formimidoyl group is derived from one intact molecule of glycine by an increment of 1 or 2&#x02009;Da respectively from (<sup>15</sup>N)- or (2&#x02212;<sup>13</sup>C &#x02212;<sup>15</sup>N)-glycine but no change from (1&#x02212;<sup>13</sup>C)-glycine (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a, b</xref>). In the EIC (selected at m/z 459.2) trace a small peak emerged other than <bold>5</bold> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>), indicating an <italic>N</italic>-iminoacetyl-glycylthricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>6</bold>) as shown by gaining 44&#x02009;Da of a carboxyl group. The <bold>6</bold> was further confirmed given an increment of 3&#x02009;Da in the presence of (1,2&#x02212;<sup>13</sup>C<sub>2</sub>&#x02212;<sup>15</sup>N)-glycine, where the moiety of <bold>5</bold> in the spectra suggested it is a daughter ionic fragment of <bold>6</bold> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). The enzymatic reactions in the presence of ST-F (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>7</bold>) alongside glycine or isotopically labeled glycine suggested that the product is <italic>N</italic>-iminoacetyl-ST-F (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>8</bold>) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d, e</xref>). NMR analysis of <bold>8</bold> purified from the reaction mixture revealed that the <italic>N</italic>-iminoacetyl group was attached to the &#x003b5;-amino group of the &#x003b2;-lysine moiety (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>; Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>The biochemical examinations for Orf1 and mutants thereof against glycylthricin and ST-F.</title><p><bold>a</bold> The EIC traces of formimidoyl-glycylthricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>5</bold>) (<italic>m</italic>/<italic>z</italic> 459.2 [M&#x02009;+&#x02009;H]<sup>+</sup>) for reactions catalyzed by (i) denatured Orf1, (ii) Orf1, (iii) C281A, (iv) C281S, (v) E312A, or (vi) F316A. <bold>b</bold> Mass spectra of <bold>5</bold> produced in the Orf1-mediated reactions in the presence of <bold>4</bold> and (i) glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;459), (ii) <sup>15</sup>N-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;460), (iii) 1-<sup>13</sup>C-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;459), or (iv) 2-<sup>13</sup>C-<sup>15</sup>N-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;461). <bold>c</bold> Mass spectra of iminoacetyl-glycylthricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>6</bold>) produced in the Orf1-mediated reactions in the presence of <bold>4</bold> and (i) glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;503), or (ii) <sup>13</sup>C<sub>2</sub>-<sup>15</sup>N-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;506). <bold>d</bold> The EIC traces of ST-F (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>7</bold>) (<italic>m</italic>/<italic>z</italic> 503.2 [M&#x02009;+&#x02009;H]<sup>+</sup>) and iminoacetyl-ST-F (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>8</bold>) (<italic>m</italic>/<italic>z</italic> 574.2 [M&#x02009;+&#x02009;H]<sup>+</sup>) for reactions catalyzed by (i) denatured Orf1, (ii) Orf1, (iii) Orf1 with addition of DTT, (iv) C281S, (v) R342A, (vi) C281S and R342A, (vii) ThiO and R342A, (viii) E426Q, (ix) E312A, or (x) F316A. <bold>e</bold> Mass spectra of the Orf1-mediated reactions in the presence of ST-F and (i) glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;574), (ii) <sup>15</sup>N-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;575), (iii) 1-<sup>13</sup>C-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;575), (iv) 2-<sup>13</sup>C-<sup>15</sup>N-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;576), or (v) <sup>13</sup>C<sub>2</sub>-<sup>15</sup>N-glycine ([M&#x02009;+&#x02009;H]<sup>+</sup>&#x02009;=&#x02009;577). Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2023_38218_Fig2_HTML" id="d32e1116"/></fig></p><p id="Par9">The kinetics for a single substrate (glycine; the first phase of the overall reaction) and double substrates (glycine + ST-F) under the pseudo-first-order condition were estimated, on which the kinetic parameters are comparable for both the single substrate (<italic>K</italic><sub>m</sub>: 202&#x02009;&#x003bc;M, <italic>k</italic><sub>cat</sub>: 0.737&#x02009;min<sup>&#x02212;1</sup>, <italic>k</italic><sub>cat</sub><italic>K</italic><sub>m</sub><sup>&#x02212;1</sup>: 0.00365&#x02009;min<sup>&#x02212;1</sup>&#x003bc;M<sup>&#x02212;1</sup>) and the double substrate (WT: <italic>K</italic><sub>m</sub>: 196&#x02009;&#x003bc;M, <italic>k</italic><sub>cat</sub>: 3.08&#x02009;min<sup>&#x02212;1</sup>, <italic>k</italic><sub>cat</sub><italic>K</italic><sub>m</sub><sup>&#x02212;1</sup>: 0.0157&#x02009;min<sup>&#x02212;1</sup>&#x003bc;M<sup>&#x02212;1</sup>; F316A: <italic>K</italic><sub>m</sub>: 190&#x02009;&#x003bc;M, <italic>k</italic><sub>cat</sub>: 7.16&#x02009;min<sup>&#x02212;1</sup>, <italic>k</italic><sub>cat</sub><italic>K</italic><sub>m</sub><sup>&#x02212;1</sup>: 0.0377&#x02009;min<sup>&#x02212;1</sup>&#x003bc;M<sup>&#x02212;1</sup>) suggesting that the glycine oxidation phase is likely the rate-limiting step (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">5</xref>, <xref rid="MOESM1" ref-type="media">6</xref>).</p><p id="Par10">To explore the substrate scope of Orf1, we assayed Orf1 against a number of clinically used aminoglycosides, including kanamycin, gentamycin, amikacin or sisomicin in the presence of glycine. Among these, only amikacin and sisomicin were found <italic>N</italic>-formimidoylation (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">7</xref>, <xref rid="MOESM1" ref-type="media">8</xref>). We subsequently assayed Orf1 versus synthetic 3-aminopropionylthricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>9</bold>), 4-aminobutylthricin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, compound <bold>10</bold>) or <bold>7</bold> in the presence of glycine. Surprisingly, in addition to the <italic>N</italic>-formimidoyl modification, a new <italic>N</italic>-glycine imine akin to that in kasugamycin was found amid the selected acceptors<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, where the ratio of <italic>N</italic>-glycine imination versus <italic>N</italic>-formimidoylation is positively proportional to the length of the sidechain (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>). The <italic>N</italic>-glycine imination is unexpected and perplexing as it is somewhat in conflict with the general FAD-mediated decarboxylation reactions (see below). Both the <italic>N</italic>-formimidoylation and -glycine imination are useful biotransformations concerning diversity-oriented diversification/complexification, not least a strategy to counter aminoglycoside-modifying enzymes (e.g. aminoglycoside-acetylating enzyme, AAC) to avoid drug resistance (see below).</p></sec><sec id="Sec4"><title>Crystal structures and substrate-binding sites</title><p id="Par11">Regarding the glycine-derived formimidoyl transfer reaction, it must proceed through a multitude of chemical reactions as mentioned above. Our instinct tells us that the enzyme should be similar to a typical FAD-dependent monooxygenase, where the oxidized imino acid intermediate should undergo a nucleophilic attack of FAD-associated peroxide, thus resulting in an oxidative decarboxylation consequence. However, an issue that arises right away is when the addition and transfer reaction take place and how it works out in sequence at the same reaction site. To crack the reaction order and corresponding mechanisms, we took advantage of X-ray crystallography, whereby snapshots of complexes in phases may help illustrate the overall reaction continuums. At the protein level, Orf1 is a flavoprotein similar to glycine oxidases ThiO and GO (both are members of the glutathione reductase 2 (GR2) family of proteins)<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup> containing two domains: one for FAD binding and the other for substrate binding (the Dali Z-score and r.m.s.d. are 41.7 and 2.4&#x02009;&#x000c5; (359&#x02009;C&#x003b1; atoms)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>, respectively). Orf1 is a protein of 491 amino acid residues longer than ThiO or GO by an additional 100 or so residues at the sequence level, which is folded into 12 &#x003b1;-helices and 17 &#x003b2;-strands into a three-dimensional (3D) structure (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a, b</xref>). It has a quaternary structure of four subunits (tetrameric) in solution. The 3D structure of Orf1 in the presence of glycine was crystallized and determined at 1.9&#x02009;&#x000c5; as illustrated in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, wherein an asymmetric unit contains 8 polypeptide chains as a result of the low-symmetry P1 point group. The quaternary structure of Orf1 was confirmed by PDBePISA with an immense tetrameric buried area (11390 &#x000c5;<sup>2</sup>)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Each individual polypeptide chain is folded into three structural domains, a FAD binding domain, a substrate binding domain and a twisted 4-helix bundle domain (additional 100 C-terminal residues in consistency with sequence analysis), which has no known function with no equivalents in all GR2 family proteins reported thus far (see below, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>), presumably taking part in protein-protein interaction at the quaternary structure level.<fig id="Fig3"><label>Fig. 3</label><caption><title>Overall structures of Orf1.</title><p><bold>a</bold> Orf1 is a tetrameric complex of a dimer of dimers in solution, of which each protomer contains a FAD prosthetic group. <bold>b</bold> Each protomer is comprised of three domains, a FAD binding domain (red), a substrate binding domain (green) and a C-terminal domain (blue). The tetrameric complex is interfaced by the substrate binding domain and the C-terminal domain. <bold>c</bold> The glycine binding site is located on the top of the <italic>re</italic> face of the isoalloxazine ring of FAD and shaped by residues A54, G55, A56, M57, Y294, H284, R342, and R368 revealed from the Orf1-glycine complex. <bold>d</bold> Sarcosine also binds to the glycine-binding site as revealed from the Orf1-sacrosine complex. <bold>e</bold> R368 is misplaced when R342 was mutated to Ala resulting in the loss of enzyme activity as revealed from the Orf1-R342A structure. <bold>f</bold> The surface presentation of the glycine binding pocket, where a cavity nearby the active site was speculated the glycylthricin binding site. <bold>g</bold> The complex structure of Orf1-glycine-glycylthricin. Each Orf1 protomer in the tetrameric complex contains one molecule of FAD, glycine and glycylthricin. <bold>h</bold> The glycylthricin binding site is located at the inter-subunit junctions, where binding pockets are formed. <bold>i</bold> The 2F<sub>o</sub>-F<sub>c</sub> density map of glycylthricin is countered at 1 &#x003c3; shown in a gray mesh. <bold>j</bold> The distance between the amine nitrogen atom of glycylthricin and the &#x003b1;-carbon of glycine is 13.5&#x02009;&#x000c5; away from each other. The antiparallel-&#x003b2;-sheet (&#x003b2;11- &#x003b2;15) acts as a physical barrier that delimits a boundary for both the glycylthricin and glycine binding pockets. <bold>k</bold> Superposition of crystal structures of wildtype and mutants in complex with glycylthricin. The Orf1-glycylthricin (B chain), C281S-glycylthricin (B chain), F316A-glycylthricin (B chain), R342A-glycylthricin (A chain) and E426Q-glycylthricin (B chain) are colored green, cyan, gray, magentas and yellow, respectively. The major binding-site residues and glycylthricin are well aligned without significant conformational changes.</p></caption><graphic xlink:href="41467_2023_38218_Fig3_HTML" id="d32e1359"/></fig></p><p id="Par12">Each single structure orchestrates two apparent binding cavities one for FAD and the other one for glycine. The FAD prosthetic cofactor in Orf1 is akin to that in other GR2 subfamily proteins, where the binding site is distant from the monomer-monomer interfaces. It adopts an extended conformation with the isoalloxazine ring compartmentalizing the FAD-binding domain and the glycine-binding domain that sits above the <italic>re</italic>-face of the isoalloxazine ring (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c&#x02013;f</xref>).</p><p id="Par13">The compartment divided by the FAD cofactor is enclosed by four splayed &#x003b2;-strands curving around the isoalloxazine ring with two loop regions that define the glycine binding site (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>). The crystals treated with glycine or sarcosine showed an extra electron density where the &#x003b1;-C atom of glycine or sarcosine is best described as a sp<sup>3</sup> configuration. Except for G55 and H284, the residues A54, M57, R368 and R342 that surround the glycine/FAD reaction center are conserved between Orf1 and ThiO in the secondary and ternary sequence level (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10</xref>). The glycine is anchored in place by: (a) N<sup>&#x003b7;2</sup> and N<sup>&#x003b5;</sup> of R342 that H-bond with the terminal carboxylate of glycine (2.8 and 2.9&#x02009;&#x000c5;) and &#x003c0;-stack with the guanidine group of R368; (b) the &#x003b1;-C atom of glycine is at a H-bonding distance to the N5 atom of the isoalloxazine ring (3.0&#x02009;&#x000c5;); (c) the amine group of glycine forms a H-bond with the carbonyl group of R368 (2.9&#x02009;&#x000c5;). H284 and Y294 are associated with each other via H-bonding (4.1&#x02009;&#x000c5;) in close proximity to the amino group (4.9&#x02009;&#x000c5;) of glycine, presumably serving as a catalytic dyad to deprotonate &#x003b1;-amine of glycine in support of the hydride transfer mechanism<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>, as the activity of site-directed mutants H284A and Y294F was compromised to some extent. Moreover, R342 is another conserved residue in GO (glycine oxidase), DAAO (<italic>D</italic>-amino acids oxidase) and SOX (sarcosine oxidase) that electrostatically interacts with the COO<sup>-</sup> group of substrates<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p><p id="Par14">An appreciable volume of a cavity (539 &#x000c5;<sup>3</sup>) close to the FAD/glycine binding site was initially considered the glycylthricin binding site, as it appears accessible through a narrow entrance for the glycyl side chain of glycylthricin to reach the oxidized glycine (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11a</xref>). The true binding site, however, is located at the tetrameric inter-junction entwined by the C-terminal four-bundle domains on the opposite side of the one misdeemed. This site will not be known until the determination of the glycylthricin-glycine-Orf1 ternary complex structure (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3g</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">12</xref>), where it is composed of two neighboring domains with a tangible volume of 1415 &#x000c5;<sup>3</sup> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3h</xref>). Glycylthricin resides nicely inside the cavity lined by interacting residues (F279, R306, S310, E313, E312, T423, E434, W435, M438, T466 and F470). Specifically, the carbamoylated <italic>D</italic>-gulosamine and streptolidine lactam moieties are held by residues E434, T423, T466 and E312 through H-bonding networks (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3i</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">13</xref>). The side chains of E312 and E434 likely experience significant conformational changes upon substrate binding (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">13</xref>). Mutant E312A confirmed the necessity of changes in recognizing substrates, whereby the binding affinity versus ST-F dropped 10-fold, in addition to losing the reactivity to form <bold>8</bold> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref> (ix); Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>). Both glycylthricin and 4-aminobutylthricin (<bold>10</bold>, a product analog) were observed in the same cavity in structures, suggesting that it is an intrinsic binding site for glycylthricin (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">12a, b</xref>). However, the glycine amine of glycylthricin is distant from the &#x003b1;-C atom of glycine in the glycine binding site as far as 13.5&#x02009;&#x000c5; (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3j</xref>). Geographically, the antiparallel-&#x003b2;-sheet (&#x003b2;11- &#x003b2;15) of the glycine binding domain serves as a physical barrier, separating glycylthricin from glycine. Such an arrangement negates multiple reactions in one site but instead supports two separate but adjacent reaction centers. Namely, the reactive product generated from glycine oxidation in the FAD-mediated reaction is safeguarded and swiftly transferred to the glycylthricin binding site, allowing subsequent addition, decarboxylation, dehydration reactions to proceed towards the <italic>N</italic>-formimidoylated or <italic>N</italic>-iminoacetylated modification in order.</p></sec><sec id="Sec5"><title>Identification of a covalently-modified adduct at C281</title><p id="Par15">In the Orf1-glycine complex structure, an extra chunk of electron density extended from the terminal thiol group of C281, which was unexpectedly spotted (the only residue out of 12 cysteine residues in a single polypeptide chain) at the glycylthricin binding site, a location next door to the glycine binding cavity and 14.7&#x02009;&#x000c5; away from the N5 of FAD (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3j</xref>). This electron density appears to exhibit two different lobes a short one and an extended one (at the &#x0201c;H subunit&#x0201d; of the structure) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). For the latter, it best fits with a <italic>trans</italic> glycine imine-N&#x02013;O&#x02013;S-C281 species based on the density contour, a structure reminiscent of the NOS bridge recently reported in transaldolases (<italic>Ng</italic>TAL), where a covalent crosslink between cysteine and lysine residues was determined as an allosteric redox switch (see below, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b, c</xref>)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. We found that the geometric properties of the glycine imine NOS bridge (N-S distance 2.64&#x02009;&#x000c5;, NOS angle 119.9&#x000b0;, N-O distance 1.4&#x02009;&#x000c5; and O-S distance 1.65&#x02009;&#x000c5;) fully comply with the criteria defined by Tittmann et al. for a NOS bridge in proteins<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. The C281 residue, nonetheless, is in a reduced form in all polypeptide chains in the structures added with no glycine. It is worth noting that each data set collected from crystal diffraction of X-ray has an accumulated average absorbed dose of 0.67 MGy, which is far lower than the dose needed to provoke radiation damage thereby suggesting that the C281-adduct is not a result of X-ray radiation but rather an intrinsic NOS covalent adduct. We reasoned that the thiol group is subject to reactive oxygen species (ROS, e.g. H<sub>2</sub>O<sub>2</sub>)-mediated cysteine oxidation to form sulfenic acid (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c), a</xref> relatively short-lived transient species, which is pivotal to its transformation to other oxidative post-translational modifications (e.g., sulfinic acid (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>) and disulfide bond)<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>.<fig id="Fig4"><label>Fig. 4</label><caption><title>The glycine imine-N&#x02013;O&#x02013;S-C281 bridge in the Orf1-glycine complex structure.</title><p><bold>a</bold> An intrinsic electron density (contrasted by 2F<sub>o</sub>-F<sub>c</sub> map contoured at 1 &#x003c3; in gray and the F<sub>o</sub>-F<sub>c</sub> map contoured at 3 &#x003c3; in green) was unexpectedly found nearby residue C281 at the glycylthricin binding site. <bold>b</bold> The chemical model that best fits into the electron density region (2F<sub>o</sub>-F<sub>c</sub> map at 1 &#x003c3; colored blue) is a glycine imine adduct in a covalent linkage to C281 through a N&#x02013;O&#x02013;S bridge. <bold>c</bold> The C281-iminoglycine adduct is surrounded by residues T298, E312, E313, F316 and E426. The distance between two atoms was labeled with a yellow dashed line. <bold>d</bold>, <bold>e</bold> Superposition of two complexes (the C281-adduct and the glycylthricin-containing structures) shows that the distance between the amine group of glycylthricin and &#x003b1;-carbon of the iminoacetate adduct is 3.1&#x02009;&#x000c5; within a general H-bond range with a Burgi-Dunitz angle of 99.7&#x000b0; in an approaching trajectory. <bold>f</bold> Superposition of WT-glycylthricin (green), E312A-glycylthricin (cyan) and C281-iminoglycine adduct (gray) reveals that E312 undergoes a substrate-induced conformational change, in which upon addition the resulting decarboxylation facilitates &#x003b2;-elimination. <bold>g</bold> Superposition of WT-glycylthricin (green), WT-4-aminobutylthricin (magenta), F316-ST-F (cyan) and C281-iminoglycine adduct (gray) shows considerable displacements of the median &#x003b3;-aminobutyl and the long &#x003b2;-lysine sidechains away from that of glycylthricin likely as a result of a geographic effect.</p></caption><graphic xlink:href="41467_2023_38218_Fig4_HTML" id="d32e1567"/></fig><fig id="Fig5"><label>Fig. 5</label><caption><title>The determination of covalent modifications of residue C281.</title><p><bold>a</bold> Mass spectrometric analyses for the C281-dimedone adduct and the sulfinylated peptide fragments of Orf1 incubated in a glycine-containing buffer solution. Detection of the AFAC<sup>281</sup>GLHLVPR peptide labeled with dimedone (+138&#x02009;Da) and the sulfinylated peptide (+33&#x02009;Da). MS/MS spectrum indicates the formation of a C281-dimedone adduct confirming the existence of the SOH group. The mass spectrometric analysis concurrently revealed that the thiol can undergo stepwise oxidation to sulfenic, sulfinic and sulfonic acid (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">29</xref>). The conversion rate for SH-Cys281 to SOH-Cys281 is fast and high. The mass spectrometry files were deposited in ProteomXchange with identifier PXD041105 and PXD041104, respectively. <bold>b</bold> A considerable amount of H<sub>2</sub>O<sub>2</sub> detected in the glycine-containing reaction solution added with ThiO (FPOX) in 3&#x02009;min in contrast to much less H<sub>2</sub>O<sub>2</sub> in the same context but added with Orf1 (FPMO). The assays of Orf1 and ThiO were run with two independent replicates (<italic>n</italic>&#x02009;=&#x02009;2) and the data were presented as mean values&#x02009;&#x000b1;&#x02009;SD. Source data are provided as a Source Data file. Photospectrometric analysis further supports Orf1 a FPMO (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">30</xref>). <bold>c</bold> The sulfonic-containing peptides (at C281) from trypsin-treated Orf1 were selected and analyzed by mass spectrometry, in that the sulfonic-containing fragment renders relatively high abundance with molecular distinctiveness. Orf1 was incubated in the presence of <bold>4</bold> or <bold>7</bold> in a H<sub>2</sub><sup>18</sup>O buffer solution 1&#x02009;h and then subjected to trypsin digestion overnight, of which the mass spectra demonstrated that the incorporation of one <sup>18</sup>O-isotopic atom in sulfonic-containing fragments occurs mainly in the reaction with <bold>7</bold> (lower panel, with an enriched M&#x02009;+&#x02009;2 peak) as opposed to that with <bold>4</bold> (upper panel, with a typical isotopic profile) in favor of the mechanism proposed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>. z&#x02009;=&#x02009;2 stands for doubly-charged positive ions in mass spectrometry. The reaction condition is the same as that for the experiments shown in Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">31c</xref>(ii) and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9e</xref>(ii). Two major products are <bold>5</bold> and <bold>8</bold>, respectively. The mass spectrometry files were deposited in ProteomXchange with identifier PXD041103.</p></caption><graphic xlink:href="41467_2023_38218_Fig5_HTML" id="d32e1648"/></fig></p><p id="Par16">To confirm this, Orf1 was incubated with glycine, digested with trypsin, treated with 5,5-dimethyl-1,3-cyclodehexadione (a reagent used to detect the appearance of sulfenic acid) and then subjected to mass spectrometry analysis<sup><xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref></sup>. The protein ID unequivocally displayed that the peptide mass is increased by 138 a.m.u. because of a sulfur-dimedone adduct, thus confirming the existence of sulfenic acid. The C281 adducts in the form of a sulfinic modification (+33&#x02009;Da) were also detected by MALDI-TOF (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>) in a manner similar to all the ramifications in C38 oxidation observed for the K8A variant of <italic>Ng</italic>TAL (the enzyme where the lysine-cysteine switch was uncovered)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>.</p><p id="Par17">To probe the importance of C281, we mutated it to alanine or serine and E426 to Q426 (a residue related to NOS-formation). Biochemical assays confirmed that the both residues and the NOS bridge are essential for the reaction to proceed, as neither one led to the end product (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a (iii, iv), d (iv, viii)</xref>). In contrast, both C281A and E426Q mutants still exhibited similar glycine oxidation activity, and the R342A lost the glycine oxidation ability but held the same ST-F binding affinity as the wild type (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>). In terms of conformations, the mutants showed no difference from the wild type except for the sidechain of R368 in the R342A mutant (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e, k</xref>). Residue R342 turned out to be critical because the sidechain of R368 was misplaced by intruding into the glycine binding site as manifested in the crystal structure of R342A (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e</xref>). Next, we performed coupled assays to detect the end product to see if it could be formed by complementary pairs C281S/R342A or ThiO/R342A (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d (vi, vii)</xref>). No product was found, suggesting that (1) glycine imine (the product of ThiO) is not the intermediate for R342A (with intact C281); (2) the first-reaction-phase product formed by C281S is water-labile and unable to transfer undamagedly from C281S to R342A. Given that <bold>4</bold> is in close proximity to the C281-S&#x02013;O&#x02013;N-glycine imine adduct (see below), the reactions, such as addition, decarboxylation, and dehydration, are likely to take place in sequence towards the formation of <italic>N</italic>-formimidoyl-glycylthricin. We also observed that 90% of the enzyme activity was lost when reactions were conducted in a DTT-containing (100&#x02009;mM) reaction solution, likely because glycine oxidation cannot proceed and/or C281 is fully reduced (underscoring the essentiality of the post-translational modification) (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>). The residues nearby the C281-adduct include T298, E312, E313, F316 and E426 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>), of which F316, E312 and E313 may cooperatively allow nucleophilic addition and cofactor-free decarboxylation reactions to proceed in sequence. Our reasoning is that F316 stabilizes the planar imine glycine adduct through the &#x003c0;-&#x003c0; stacking interaction. The importance of this residue was ascertained by mutational experiments, whereby F316A brings on <bold>6</bold> as the major product (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a (vi)</xref>). Overlaying two complexes (the C281-adduct and the glycylthricin-containing structures) reveals that the glycylthricin ligand is positioned by residues E312 and E313 in place, making the terminal amine group of glycylthricin in close proximity to the &#x003b1;-carbon of the oximinoacetate adduct by 3.1&#x02009;&#x000c5; with a Burgi-Dunitz angle of 99.7&#x000b0; an approach trajectory (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d, e</xref>). The nucleophilicity of the terminal amine may be enhanced after deprotonation by the main chain carbonyl group of N299 (2.7&#x02009;&#x000c5;). The attack of the amine group from the <italic>re</italic> face onto the F316-stabilized C281-adduct should reconfigure the planar (sp<sup>2</sup>) <italic>trans</italic> imine to a tetrahedral (sp<sup>3</sup>, <italic>S</italic>-configuration) geminal diamine species, whereby the &#x003c0;-&#x003c0; stabilization no longer holds. The charged carboxyl group is neutralized after the entropy-driven decarboxylation reaction ensuing in response to the repulsion force incited between the charged and hydrophobic groups. The left electron lone pair could flow into the &#x003c3;-antibonding orbital of the nitrogen atom of the anti-periplanar N&#x02013;O&#x02013;S bridge in a way akin to an E2-like elimination reaction, which differs to the canonical PLP or thiamine-dependent (both cofactors serving as an electron sink) decarboxylation reactions. E312 another key residue collaborates with F316 to facilitate the decarboxylative reaction by introducing a repulsive electrostatic force. The fact is that the residue experiences a substrate-induced conformational change bringing the terminal carboxylate group in a short distance (3.3&#x02009;&#x000c5;) to the carboxylate group of the oximinoacetate moiety (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4f</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">13</xref>) evidenced by mutational experiments whereby compound <bold>6</bold> becomes the major product in the presence of E312A (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a (v)</xref>). As a result, E312 undergoes a substrate-induced conformational change, in which upon addition the induced decarboxylation should facilitate &#x003b2;-elimination. On the other hand, superposition of the F316A-ST-F and C281-adduct complex displays that the long side chain of ST-F is subject to a geographic effect (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4g</xref>), resulting in flipping of the amide group away from E312 to accommodate the entire aliphatic sidechain. This posture is somewhat unexpected as the &#x003b5;-amine of the &#x003b2;-lysine is a bit extended away from the &#x003b1;-carbon of the oximinoacetate adduct likely due to the absence of the phenyl ring (F316A). E312 not only recognizes the streptolidine base but also ushers the &#x003b2;-lysine to crawl into the binding site in a compact manner. In this context, E312A is able to catalyze the formation of <bold>5</bold> and <bold>6</bold> but no more <bold>8</bold>, as opposed to F316A, which catalyzes the formation of <bold>8</bold>, the dominant product (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a (v), d (ix, x)</xref>).</p></sec><sec id="Sec6"><title>Catalytic mechanisms</title><p id="Par18">Since the glycine imine is not the intermediate based on the coupled assays (ThiO/R342A and C281S/R342A), a glycine imine-like reactive intermediate produced at the FAD-reaction center should act on the relatively electrophilic sulfur of C281-SOH to give rise to the glycine imine-N&#x02013;O&#x02013;S-C281 adduct. This reactive species is not trappable because of water lability. This reactive species formed at the first reaction center is tunneled to the second one, where it is placed with its carboxylic group in association with the Glu426-water dyad. One tunnel that possibly channels the oxidized glycine into the <italic>N</italic>-formimidoylation site was located using CAVER 3.0 there are four predicted tunnels around the FAD/glycine reaction center one for the oxidized glycine channeling and the other three for entrance of glycine, (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11a</xref>)<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Five residues that constitute the tunnel and would block the intermediate tunneling if mutated were individually made (L124D, L124E, A278V, A280S and H419Y). Except for insoluble L124E, all the mutants L124D, A278V and H419Y lost the <italic>N</italic>-iminoacetylation activity unable to form <bold>8</bold>, while they are still structurally sound and active for glycine oxidation (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11b, c</xref>). The intermediate should be analogous to <italic>N</italic>-OH-glycine imine or equivalents (e.g., glycine epoxide (carboxyl oxaziridine), or cyclic glycine peroxide) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). This given setting aligns the nucleophilic hydroxylamine towards the electrophilic sulfur atom of C281-SOH, resulting in the <italic>trans</italic> oximinoglycine with a N&#x02013;O&#x02013;S covalent linkage to the protein. The adduct is stabilized by the Glu426-water dyad through a low barrier H-bond (2.5&#x02009;&#x000c5;) and poised for a nucleophilic addition reaction with glycylthricin as described above. To our knowledge, the NOS-mediated decarboxylation is unorthodox to all known biological decarboxylation reactions, not least &#x003b1;-amino acids that typically require a pyridoxal-phosphate cofactor<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The protein-NOS-mediated decarboxylation reaction empirically follows the heterolytic ionic mechanism because no radical signal was detected by EPR as that of glycyl radical enzymes (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3d</xref>). Notwithstanding other likelihoods, several oxime-like precedents do exist. For instance, the plant cytochrome P450 monooxygenase (Cyp79A1) in the biosynthesis of cyanogenic glucoside dhurrin is a close example<sup><xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>. Cyp79A1 catalyzes two consecutive <italic>N</italic>-hydroxylation reactions to yield <italic>N</italic>,<italic>N</italic>-(OH)<sub>2</sub>-tyrosine, which then undergoes dehydration and tautomerization to &#x003b1;-nitrosocarboxylic acid. The resulting &#x003b1;-nitroso species serves as an electron sink and is protonated intermolecularly by the terminal carboxylic acid leading to (<italic>E</italic>)-<italic>p</italic>-hydroxyphenylacetaldoxime (retaining the N&#x02013;O linkage) upon decarboxylation. In the present study, the N&#x02013;O linkage of oximinoglycine is cleaved as a consequence of nonoxidative decarboxylation, whereby C281-SOH is pushed away in a good leaving group manner. On the other hand, given ST-F the reaction gives rise to <italic>N</italic>-iminoacetyl glycinthricin, where the terminal carboxylic group is retained and the N&#x02013;O bond undergoes dehydration afterwards. This N&#x02013;O&#x02013;S bridge acts as though a linkage rod with two scissile bonds. The chain length of the nucleophile is another determinant, of which the stress/strain provoked in the binding site as well as the trajectory of the nucleophilic addition reaction together leverages the bond cleavage at either the nitroxide (N&#x02013;O) or sulfur oxide (O&#x02013;S) site (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>).</p></sec><sec id="Sec7"><title>Orf1 counteracts SttE</title><p id="Par19">Almost all ST BGCs encode a ST-resistant <italic>N</italic>-acetyl transferase (NAT), a self-resistance enzyme, that acts on STs. Given the <italic>stt</italic>E gene encoded in the <italic>Streptomyces lavendulae</italic> BCRC12163, the gene product was expressed and subjected to probe its drug resistance scope. A new major peak emerged on the LC trace in a reaction solution containing acetyl-CoA, glycylthricin and SttE when compared with control in which SttE was omitted or glycylthricin was replaced by <italic>N</italic>-formimidoyl glycylthricin (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">14</xref>). The mass-spectrometric analysis showed that the molecular weight of the peak is increased by 42&#x02009;Da in the solution containing <bold>4</bold>, suggesting that glycylthricin but not <bold>5</bold> is subject to <italic>N</italic>-acetylation. In the microbial susceptibility assay, the <italic>E. coli</italic> test strain that harbored a <italic>stt</italic>E-containing plasmid displayed a diminished inhibition zone, in which glycylthricin or ST-F was added, indicating that SttE is a ST-modifying enzyme and the <italic>N</italic>-fomimidylation or <italic>N</italic>-iminoglycination is antagonistic towards the acetylation of SttE (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">15</xref>). The bifunctional aminoglycoside modifying enzyme AAC(6&#x02019;)-Ie-APH(6&#x0201d;)-Ia inactivated glycylthricin by <italic>N</italic>-acetylation to some extent in in vitro assay (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">16</xref>)<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, while the <italic>N</italic>-formimidoylated glycylthricin was not sensitive to this given modifying enzyme. It is likely owing to the steric hindrance, reaction orientation as well as the reduced nucleophilicity of the sp<sup>2</sup>
<italic>N</italic>-formimidoyl group of <bold>5</bold> where the double bond may resonate between two nitrogen atoms at the terminal of the side chain.</p><p id="Par20">We then determined the structures of SttE in complex with ST-F or glycylthricin with CoA, of which crystals were packed in space group P1 and P212121 and determined at resolutions of 2.42 and 2.36&#x02009;&#x000c5;, respectively (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">17</xref>). The structure of SttE revealed a single core domain of a general control non-derepressible 5 (GCN5)-related <italic>N</italic>-acetyltransferase (GNAT) architecture, which is composed of seven extended &#x003b2;-strands and three &#x003b1;-helices. Both the extended strand &#x003b2;7 and &#x003b2;-hairpin between &#x003b1;A and &#x003b2;2 establish the substantial protein interface promoting protein dimerization, where D164 specifically interacts with R101 and W139 via electrostatic interactions. These binary complexes identified two ligand-binding sites where strands &#x003b2;3 and &#x003b2;4 splay out evolving a typical &#x003b2;-bulge motif. The AcCoA donor sits astride the fork with the acyl head facing the sidechain of the glycylthricin acceptor. The AcCoA binding site is composed of &#x003b2;4, &#x003b1;B, &#x003b2;5 and &#x003b1;C. Glycylthricin, on the other hand, is held by interacting residues (K75, F59, P60, D63, G54, W98, E105, D106, E141, T143, L167, Y168, S173 and E176), which as a whole define the ST binding site. In brief, residues D63, E141 interact with the guanidino group of streptolidine lactam by three H-bonds, while residues S176 and E176 associate the carbamoylated D-gulosamine with two H-bonds. The amine group is in close proximity to the sulfur atom of CoA in distances of 3.3&#x02013;4.8&#x02009;&#x000c5; (c.f. SttE-glycylthricin vs. SttE-ST-F). D106 appears to be the base deprotonating the &#x003b2;-amine group for the acetylation modification to take place, while it is a bit far away from the terminal amine group of <bold>4</bold>. Its nucleophilicity, nonetheless, may well be enhanced by two mainchain oxo groups (E105 and E141), thus accounting for the equivalent activity of SttE towards <bold>4</bold> and <bold>7</bold> (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">17c</xref>).</p><p id="Par21">In this study we report on a noncanonical FAD-dependent enzyme, Orf1, classified in the group-transferase protein family that contains two adjacent but separate reaction centers. The first center runs a FAD-mediated oxidation-oxygenation dual reaction to give rise to a <italic>N</italic>-hydroxyl glycine imine-like product in a net 4-electron oxidation manner. The second center is 13.5&#x02009;&#x000c5; away from the first one, where residue C281 plays an indispensable role. To become a fully active enzyme, the sulfhydryl group of C281 undergoes a post-translational modification with ROS (e.g., leaking H<sub>2</sub>O<sub>2</sub> from the FAD-dependent reaction) to sulfenic acid (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). The sulfenic group is capable of reacting with an oxygenated glycine imine species passed down from the first reaction center via a subtle one-way tunnel to form the NOS-covalent adduct. This enzyme-bound adduct then reacts with glycinothricin or glycylthricin following a barrage of chemical reactions, including nucleophilic addition, cofactor-free decarboxylation, &#x003b2;-elimination and dehydration, to bring on BD-12 (<italic>N</italic>-formimidoyl glycylthricin). This group-transfer modification is unprecedented as it seamlessly integrates two unrelated chemical strategies at two separate locations in one single enzyme by utilizing oligomerization to invent a second reaction center/substrate binding site. The resultant <italic>N</italic>-formimidoylation is no longer sensitive to AAC aminoglycoside-modifying enzymes, a biochemical strategy that the producing strain evolved to reinvigorate its armory to counter the orthodox drug-resistance mechanism leveraged by competing species. The substrate scope of the enzyme is not limited to the innate ones but is expandable at both ends of donors and acceptors, thereby befitting as a versatile biocatalyst in view of diversifying/complexifying privileged compounds. The NOS-mediated chemistry catalyzed by Orf1 should not be the sole case, the sequence fingerprint characterizing the activity associated with this type of chemistry may guide in finding more enzymes featuring the same mechanism (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>).</p></sec></sec><sec id="Sec8"><title>Methods</title><sec id="Sec9"><title>Cloning and protein purification</title><p id="Par22">The <italic>orf1</italic> gene was amplified from the BD-12 producing strain <italic>Streptomyces luteocolor</italic> ATCC29775<sup>(ref24)</sup>. The <italic>orf1</italic>-containing pET28a was transformed into the <italic>Escherichia coli</italic> BL21 (DE3) strain. One liter LB medium containing 50&#x02009;mg&#x02009;l<sup>&#x02212;1</sup> kanamycin was cultured at 37&#x02009;&#x000b0;C until A<sub>600</sub> reaching 0.6 and induced with 0.2&#x02009;mM isopropyl &#x003b2;-D-thiogalactopyranoside (IPTG). After 20&#x02009;h of incubation at 16&#x02009;&#x000b0;C, the cells were harvested by centrifugation and ruptured by sonication in 30&#x02009;ml lysis buffer (20&#x02009;mM phosphate pH 8.0, 500&#x02009;mM NaCl, 20&#x02009;mM imidazole and 5% (v/v) glycerol). Cell debris was span down by centrifugation (48000&#x02009;<italic>g</italic>). Supernatants were loaded into a 5&#x02009;ml Ni<sup>2+</sup>-NTA column and washed with 50&#x02009;ml lysis buffer. Yellow Orf1 was eluted with 25&#x02009;ml elution buffer (20&#x02009;mM phosphate pH 8.0, 500&#x02009;mM NaCl, 250&#x02009;mM imidazole and 5% (v/v) glycerol). Protein was further purified by size-exclusion chromatography with a Hiload 16/60 Superdex 200&#x02009;pg column under an isocratic condition (20&#x02009;mM Tris-HCl pH 7.5 and 150&#x02009;ml NaCl), and its purity was estimated by 10% SDS-PAGE. Protein concentrations ware determined using NanoDrop. The primers for site-directed mutagenesis were designed by QuikChange (Agilent) and synthesized by Genomics (Taipei) (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>). All mutants were confirmed by DNA sequencing, and corresponding proteins were purified using the same protocol for wild-type Orf1. The <italic>thiO</italic> gene was amplified from the <italic>Escherichia coli</italic> JM109 strain. The <italic>sttE</italic> gene was cloned from the <italic>Streptomyces lavendulae</italic> BCRC 12163 strain<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The <italic>aac(6</italic><italic>&#x02019;</italic><italic>)-Ie-aph(2</italic><italic>&#x0201d;</italic><italic>)-Ia</italic> gene<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> was synthesized by Genomics (Teipei). Both ThiO and SttE were expressed and purified using the same protocol as that for Orf1 (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">18</xref>, <xref rid="MOESM1" ref-type="media">19</xref>).</p></sec><sec id="Sec10"><title>Crystallization and data collection</title><p id="Par23">Orf1 and its mutants were crystallized using the hanging-drop vapor diffusion method at 20&#x02009;&#x000b0;C. The protein was concentrated to 15&#x02009;mg&#x02009;ml<sup>&#x02212;1</sup> in 25&#x02009;mM HEPES pH 7.5 and mixed with the same volume of the reservoir solution (0.1&#x02009;M Tris-HCl pH 8.5, 0.2&#x02009;M KBr, 8% (w/v) PEG 550 MME and 8% (w/v) PEG 20000). After a week incubation, the complex crystals were prepared by soaking 10&#x02009;mM substrates for 5&#x02009;mins. The crystals were immersed in 30% (v/v) glycerol as the cryoprotectant and frozen with liquid nitrogen. All X-ray diffraction data were collected using ADSQ Quantum 315, MX300-HE or EIGER2 16&#x02009;M detectors at 100&#x02009;K on beamlines TLS-13B1, TLS-15A1, TPS-05A and TPS-07A at the National Synchrotron Radiation Research Center (NSRRC), Taiwan. The datasets were indexed and scaled to P1 space group using the HKL2000 package<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. The diffraction-weighted dose for the C281-iminoglycine dataset was calculated using RADDOSE-3D (beam size ~200&#x02009;&#x003bc;m, flux ~3.01E&#x02009;+&#x02009;12 photon/sec and attenuation ~68.3%)<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. The crystals of SttE were obtained from the 15&#x02009;mg&#x02009;ml<sup>&#x02212;1</sup> protein mixed with 3&#x02009;mM ST-F or 3&#x02009;mM glycylthricin and 3&#x02009;mM coenzyme A in the reservoir solution (0.1&#x02009;M MES pH 6.5, 0.2&#x02009;M ammonium sulfate and 12.5% (w/v) PEG 8000).</p></sec><sec id="Sec11"><title>Structure determination and refinement</title><p id="Par24">Orf1 and SttE structures were determined by using the molecular replacement method MOLREP<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. The search model was generated from the FFAS03 server<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> using ThiO (PDB code <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb1NG3/pdb">1NG3</ext-link>) and SttE&#x02019;s homolog (PDB code <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb3PP9/pdb">3PP9</ext-link>) as the templates, respectively. Polypeptide models were built and refined with REFMAC5 and COOT<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref></sup>. Detailed refinement statistics are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The omit maps were generated using PHENIX<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Structural figures were plotted using PyMOL.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Data collection and refinement statistics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Orf1-Apo</th><th>Orf1-glycine</th><th>Orf1-sarcosine</th></tr><tr><th>pdb code</th><th>7XYE</th><th>7XQA</th><th>7XXD</th></tr></thead><tbody><tr><td><bold>Data collection</bold></td><td>P1</td><td>P1</td><td>P1</td></tr><tr><td colspan="4">Space group</td></tr><tr><td colspan="4">Cell dimensions</td></tr><tr><td>&#x000a0;&#x000a0;<italic>&#x02003;a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td>103.7, 108.5, 134.9</td><td>103.4, 107.8, 134.8</td><td>103.9, 108.9, 134.7</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;&#x003b1;, &#x003b2;, &#x003b3; (&#x000b0;)</td><td>90.1, 90, 83.8</td><td>89.9, 90, 83.6</td><td>90.02, 90, 83.3</td></tr><tr><td>Resolution (&#x000c5;)</td><td>30&#x02013;2.47 (2.56&#x02013;2.47)<sup>a</sup></td><td>30&#x02013;1.93 (2.00&#x02013;1.93)</td><td>30&#x02013;1.98 (2.05&#x02013;1.98)</td></tr><tr><td><italic>R</italic><sub>merge</sub></td><td>5.8 (41.0)</td><td>4.3 (23.2)</td><td>5.9 (79.3)</td></tr><tr><td><italic>I</italic> / &#x003c3;<italic>I</italic></td><td>23.4 (3.2)</td><td>35.8 (5.9)</td><td>25.6 (2.1)</td></tr><tr><td>Completeness (%)</td><td>97.5 (93.0)</td><td>97.9 (96.5)</td><td>98.0 (96.8)</td></tr><tr><td>Redundancy</td><td>4.4 (4.3)</td><td>5.3 (5.3)</td><td>4.6 (4.3)</td></tr><tr><td colspan="4"><bold>Refinement</bold></td></tr><tr><td>&#x000a0;Resolution (&#x000c5;)</td><td>29.7&#x02013;2.48 (2.55&#x02013;2.48)</td><td>29.7&#x02013;1.93 (1.98&#x02013;1.93)</td><td>28.7 &#x02212;1.98 (2.03&#x02013;1.98)</td></tr><tr><td>&#x000a0;No. reflections</td><td>195367</td><td>424882</td><td>379436</td></tr><tr><td>&#x000a0;<italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub></td><td>22.0, 24.7</td><td>19.2, 20.8</td><td>21.2, 23.5</td></tr><tr><td>&#x000a0;No. atoms</td><td>30359</td><td>32835</td><td>32439</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Protein</td><td>29090</td><td>29239</td><td>29208</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Ligand/ion</td><td>424</td><td>474</td><td>472</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Water</td><td>845</td><td>3122</td><td>2759</td></tr><tr><td><italic>B</italic>-factors</td><td>41.7</td><td>23.6</td><td>32.7</td></tr><tr><td>&#x000a0;&#x02003;Protein</td><td>45.2</td><td>25.0</td><td>34.8</td></tr><tr><td>&#x000a0;&#x02003;Ligand/ion</td><td>41.3</td><td>22.3</td><td>35.4</td></tr><tr><td>&#x000a0;&#x02003;Water</td><td>32.8</td><td>30.5</td><td>39.2</td></tr><tr><td colspan="4">R.m.s. deviations</td></tr><tr><td>&#x000a0;&#x02003;Bond lengths (&#x000c5;)</td><td>0.007</td><td>0.007</td><td>0.007</td></tr><tr><td>&#x000a0;&#x02003;Bond angles (&#x000b0;)</td><td>1.46</td><td>1.37</td><td>1.42</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th/><th>Orf1-glycine-4</th><th>Orf1-glycine-10</th><th>C281S-glycine-4</th></tr><tr><th>pdb code</th><th>7XXC</th><th>7XXM</th><th>7XX0</th></tr></thead><tbody><tr><td><bold>Data collection</bold></td><td>P1</td><td>P1</td><td>P1</td></tr><tr><td colspan="4">Space group</td></tr><tr><td colspan="4">Cell dimensions</td></tr><tr><td>&#x000a0;&#x000a0;<italic>&#x02003;a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td>103.5, 108.1, 134.6</td><td>103.4, 107.2, 135.2</td><td>103.7, 108.1, 135.8</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;&#x003b1;, &#x003b2;, &#x003b3; (&#x000b0;)</td><td>89.8, 90.1, 96.5</td><td>90.1, 90.04, 83.7</td><td>90.1, 90, 96.6</td></tr><tr><td>Resolution (&#x000c5;)</td><td>30&#x02013;1.99 (2.06&#x02013;1.99)</td><td>30&#x02013;2.05 (2.12&#x02013;2.05)</td><td>30&#x02013;2.20 (2.28&#x02013;2.20)</td></tr><tr><td><italic>R</italic><sub>merge</sub></td><td>3.7 (25.6)</td><td>4.7 (60.0)</td><td>5.9 (52.3)</td></tr><tr><td><italic>I</italic> / &#x003c3;<italic>I</italic></td><td>38.1 (5.8)</td><td>30 (2.5)</td><td>24.9 (3.6)</td></tr><tr><td>Completeness (%)</td><td>97.5 (93.2)</td><td>98.2 (97.1)</td><td>97.5 (96.3)</td></tr><tr><td>Redundancy</td><td>5.2 (5.2)</td><td>4.6 (4.5)</td><td>4.6 (4.4)</td></tr><tr><td colspan="4"><bold>Refinement</bold></td></tr><tr><td>&#x000a0;Resolution (&#x000c5;)</td><td>27.8&#x02013;1.99 (2.04&#x02013;1.99)</td><td>29.4&#x02013;2.12 (2.17&#x02013;2.12)</td><td>29.9&#x02013;2.20 (2.26&#x02013;2.20)</td></tr><tr><td>&#x000a0;No. reflections</td><td>387913</td><td>302700</td><td>289233</td></tr><tr><td>&#x000a0;<italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub></td><td>19.8, 22.1</td><td>19.5, 21.5</td><td>18.4, 20.6</td></tr><tr><td>&#x000a0;No. atoms</td><td>32355</td><td>32019</td><td>32003</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Protein</td><td>29225</td><td>28875</td><td>29215</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Ligand/ion</td><td>704</td><td>720</td><td>704</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Water</td><td>2426</td><td>2424</td><td>2084</td></tr><tr><td><italic>B</italic>-factors</td><td>29.4</td><td>31.0</td><td>33.8</td></tr><tr><td>&#x000a0;&#x02003;Protein</td><td>32.2</td><td>32.8</td><td>36.2</td></tr><tr><td>&#x000a0;&#x02003;Ligand/ion</td><td>27.7</td><td>47.7</td><td>36.0</td></tr><tr><td>&#x000a0;&#x02003;Water</td><td>33.7</td><td>35.3</td><td>38.5</td></tr><tr><td colspan="4">R.m.s. deviations</td></tr><tr><td>&#x000a0;&#x02003;Bond lengths (&#x000c5;)</td><td>0.007</td><td>0.007</td><td>0.007</td></tr><tr><td>&#x000a0;&#x02003;Bond angles (&#x000b0;)</td><td>1.42</td><td>1.41</td><td>1.41</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th/><th>R342A-4</th><th>E426Q-glycine-4</th><th>F316A-glycine-7</th></tr><tr><th>pdb code</th><th>7XXR</th><th>7XYL</th><th>7XXP</th></tr></thead><tbody><tr><td><bold>Data collection</bold></td><td>P1</td><td>P1</td><td>P1</td></tr><tr><td colspan="4">Space group</td></tr><tr><td colspan="4">Cell dimensions</td></tr><tr><td>&#x000a0;&#x000a0;<italic>&#x02003;a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td>103.4, 107.9, 133.4</td><td>103.4, 107.4, 135</td><td>103.3, 106.4, 135.5</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;&#x003b1;, &#x003b2;, &#x003b3; (&#x000b0;)</td><td>90.1, 90, 96.3</td><td>89.98, 89.99,83.6</td><td>90, 90.01, 96.2</td></tr><tr><td>Resolution (&#x000c5;)</td><td>30&#x02013;2.40 (2.49&#x02013;2.40)</td><td>30&#x02013;2.10 (2.18&#x02013;2.10)</td><td>30&#x02013;2.05 (2.12&#x02013;2.05)</td></tr><tr><td><italic>R</italic><sub>merge</sub></td><td>6.0 (64.2)</td><td>5.4 (66.1)</td><td>8.1 (61.7)</td></tr><tr><td><italic>I</italic> / &#x003c3;<italic>I</italic></td><td>25.0 (2.7)</td><td>29.6 (2.4)</td><td>17.5 (2.4)</td></tr><tr><td>Completeness (%)</td><td>98.5 (97.7)</td><td>98.2 (97.1)</td><td>97.5 (93.2)</td></tr><tr><td>Redundancy</td><td>4.4 (4.3)</td><td>4.9 (4.3)</td><td>4.3 (3.9)</td></tr><tr><td colspan="4"><bold>Refinement</bold></td></tr><tr><td>&#x000a0;Resolution (&#x000c5;)</td><td>28.6&#x02013;2.40 (2.46&#x02013;2.40)</td><td>28.1 &#x02212;2.10 (2.15&#x02013;2.10)</td><td>29.9&#x02013;2.05 (2.04&#x02013;1.99)</td></tr><tr><td>&#x000a0;No. reflections</td><td>212738</td><td>319322</td><td>347963</td></tr><tr><td>&#x000a0;<italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub></td><td>20.0, 22.0</td><td>19.7, 22.3</td><td>18.8, 20.8</td></tr><tr><td>&#x000a0;No. atoms</td><td>30395</td><td>32497</td><td>31707</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Protein</td><td>29176</td><td>29212</td><td>29136</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Ligand/ion</td><td>664</td><td>704</td><td>744</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;Water</td><td>555</td><td>2548</td><td>1827</td></tr><tr><td><italic>B</italic>-factors</td><td>43.2</td><td>31.8</td><td>29.9</td></tr><tr><td>&#x000a0;Protein</td><td>46.5</td><td>35.2</td><td>31.9</td></tr><tr><td>&#x000a0;Ligand/ion</td><td>52.4</td><td>29.9</td><td>30.8</td></tr><tr><td>&#x000a0;Water</td><td>32.9</td><td>38.9</td><td>32.1</td></tr><tr><td colspan="4">R.m.s. deviations</td></tr><tr><td>&#x000a0;&#x02003;Bond lengths (&#x000c5;)</td><td>0.008</td><td>0.007</td><td>0.008</td></tr><tr><td>&#x000a0;&#x02003;Bond angles (&#x000b0;)</td><td>1.48</td><td>1.41</td><td>1.49</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th/><th>F316A-glycine-4</th><th>E312A-glycine-4</th></tr><tr><th>pdb code</th><th>7Y0X</th><th>8GRI</th></tr></thead><tbody><tr><td><bold>Data collection</bold></td><td>P1</td><td>P1</td></tr><tr><td colspan="3">Space group</td></tr><tr><td colspan="3">Cell dimensions</td></tr><tr><td>&#x000a0;&#x000a0;<italic>&#x02003;a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td>103.6, 107.9, 134.8</td><td>103.3, 108.1, 133.5</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;&#x003b1;, &#x003b2;, &#x003b3; (&#x000b0;)</td><td>89.96, 90.1, 83.4</td><td>89.8, 89.98, 96.4</td></tr><tr><td>Resolution (&#x000c5;)</td><td>30&#x02013;2.12 (2.20&#x02013;2.12)</td><td>30&#x02013;2.37 (2.45&#x02013;2.37)</td></tr><tr><td><italic>R</italic><sub>merge</sub></td><td>5.7 (60.8)</td><td>8.6 (63.1)</td></tr><tr><td><italic>I</italic> / &#x003c3;<italic>I</italic></td><td>28 (2.8)</td><td>17.6 (2.4)</td></tr><tr><td>Completeness (%)</td><td>97.4 (91.2)</td><td>99.3 (99)</td></tr><tr><td>Redundancy</td><td>4.2 (4.3)</td><td>5.1 (5.1)</td></tr><tr><td colspan="3"><bold>Refinement</bold></td></tr><tr><td>&#x000a0;Resolution (&#x000c5;)</td><td>27.7&#x02013;2.05 (2.10&#x02013;2.05)</td><td>29.7&#x02013;2.37 (2.43&#x02013;2.37)</td></tr><tr><td>&#x000a0;No. reflections</td><td>352917</td><td>211837</td></tr><tr><td>&#x000a0;<italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub></td><td>19.9, 21.5</td><td>20.9, 23.3</td></tr><tr><td>No. atoms</td><td>31217</td><td>30454</td></tr><tr><td>&#x000a0;&#x02003;Protein</td><td>29118</td><td>29064</td></tr><tr><td>&#x000a0;&#x02003;Ligand/ion</td><td>704</td><td>704</td></tr><tr><td>&#x000a0;&#x02003;Water</td><td>1395</td><td>686</td></tr><tr><td><italic>B</italic>-factors</td><td>29.3</td><td>42.0</td></tr><tr><td>&#x000a0;&#x02003;Protein</td><td>31.4</td><td>45.3</td></tr><tr><td>&#x000a0;&#x02003;Ligand/ion</td><td>32.1</td><td>43.4</td></tr><tr><td>&#x000a0;&#x02003;Water</td><td>30.5</td><td>33.5</td></tr><tr><td colspan="3">R.m.s. deviations</td></tr><tr><td>&#x000a0;&#x02003;Bond lengths (&#x000c5;)</td><td>0.007</td><td>0.006</td></tr><tr><td>&#x000a0;&#x02003;Bond angles (&#x000b0;)</td><td>1.44</td><td>1.37</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th/><th>SttE-CoA-4</th><th>SttE-7</th></tr><tr><th>pdb code</th><th>7YPU</th><th>7YPV</th></tr></thead><tbody><tr><td><bold>Data collection</bold></td><td>P212121</td><td>P1</td></tr><tr><td colspan="3">Space group</td></tr><tr><td colspan="3">Cell dimensions</td></tr><tr><td>&#x000a0;&#x000a0;<italic>&#x02003;a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td>52.4, 102.8, 386.4</td><td>48.7, 77.8, 109</td></tr><tr><td>&#x000a0;&#x000a0;&#x02003;&#x003b1;, &#x003b2;, &#x003b3; (&#x000b0;)</td><td>90, 90, 90</td><td>89.95, 90.1,89.99</td></tr><tr><td>Resolution (&#x000c5;)</td><td>30&#x02013;2.36 (2.44&#x02013;2.36)</td><td>20&#x02013;2.42 (2.51&#x02013;2.42)</td></tr><tr><td><italic>R</italic><sub>merge</sub></td><td>5.8 (37.2)</td><td>6.6 (43.9)</td></tr><tr><td><italic>I</italic> / &#x003c3;<italic>I</italic></td><td>39.4 (6.5)</td><td>15.2 (3.8)</td></tr><tr><td>Completeness (%)</td><td>99.7 (98.9)</td><td>97.9 (96.9)</td></tr><tr><td>Redundancy</td><td>10.2 (8.9)</td><td>2.8 (2.7)</td></tr><tr><td colspan="3"><bold>Refinement</bold></td></tr><tr><td>&#x000a0;Resolution (&#x000c5;)</td><td>29.8&#x02013;2.36 (2.42&#x02013;2.36)</td><td>19.9&#x02013;2.42 (2.48&#x02013;2.42)</td></tr><tr><td>&#x000a0;No. reflections</td><td>82980</td><td>56666</td></tr><tr><td>&#x000a0;<italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub></td><td>19.7, 22.3</td><td>21.1, 24.5</td></tr><tr><td>No. atoms</td><td>10706</td><td>11119</td></tr><tr><td>&#x000a0;&#x02003;Protein</td><td>9937</td><td>10302</td></tr><tr><td>&#x000a0;&#x02003;Ligand/ion</td><td>450</td><td>280</td></tr><tr><td>&#x000a0;&#x02003;Water</td><td>319</td><td>537</td></tr><tr><td><italic>B</italic>-factors</td><td>33.3</td><td>34.4</td></tr><tr><td>&#x000a0;&#x02003;Protein</td><td>35.0</td><td>37.2</td></tr><tr><td>&#x000a0;&#x02003;Ligand/ion</td><td>61.4</td><td>30.1</td></tr><tr><td>&#x000a0;&#x02003;Water</td><td>35.0</td><td>35.7</td></tr><tr><td colspan="3">R.m.s. deviations</td></tr><tr><td>&#x000a0;&#x02003;Bond lengths (&#x000c5;)</td><td>0.006</td><td>0.005</td></tr><tr><td>&#x000a0;&#x02003;Bond angles (&#x000b0;)</td><td>1.42</td><td>1.41</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Values in parentheses are for highest-resolution shell.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Mass spectrometry analysis of Orf1</title><p id="Par25">To perform mass spectrometry analysis of the C281-dimedone adduct, 0.2&#x02009;mM Orf1 was incubated with 1&#x02009;mM glycine 37&#x02009;&#x000b0;C for 10&#x02009;mins and added with 10&#x02009;mM dimedone at room temperature for another 30&#x02009;mins. The reaction solution was exchanged to a buffer solution containing 25&#x02009;mM NH<sub>4</sub>HCO<sub>3</sub> with 40&#x02009;&#x003bc;g&#x02009;&#x003bc;l<sup>&#x02212;1</sup> trypsin. After overnight incubation at 37&#x02009;&#x000b0;C, the sample (2&#x02009;&#x003bc;g &#x003bc;l<sup>&#x02212;1</sup>) was injected at a flow rate of 50&#x02009;&#x003bc;l ml<sup>&#x02212;1</sup> into an ACQUITY UPLC CSH C18 peptide column (130&#x02009;&#x000c5;, 1&#x02009;mm&#x02009;&#x000d7;&#x02009;150&#x02009;mm, 1.7&#x02009;&#x003bc;m, #186006935) and detected by LC-ESI-MS, a Waters SELECT SERIES<sup>TM</sup> Cyclic IMS QToF (Manchester, UK). In brief, the gradient was set with 98% (v/v) buffer A for 3&#x02009;mins to 60% (v/v) buffer B over 20&#x02009;mins, where buffer A was water with 0.1% (v/v) formic acid and buffer B was acetonitrile with 0.1% (v/v) formic acid. The mass was operated in the LC/MS<sup>E</sup> mode of data acquisition, where alternating 1&#x02009;second scans for low (4&#x02009;V) or high (10-40&#x02009;V) collision energies with lock mass. The Byonic software 4.2.10 (protein metric) was used for peptide identification. The search parameter was set as: precursor mass tolerance ~20 ppm, fragment mass tolerance ~20 ppm, maximum missed cleavages ~5, and cysteine carbamidomethylation (+57.021464), oxidation (+15.994915), dimedone adduct (+138.068068) and methionine oxidation (+15.994915) with target protein database. Orf1 (45&#x02009;&#x003bc;M) was incubated in the presence of 2.5&#x02009;mM glycine and 5&#x02009;mM <bold>4</bold> or <bold>7</bold> at 37&#x02009;&#x000b0;C for 1&#x02009;hour in 92.2% (v/v) H<sub>2</sub><sup>18</sup>O. The reaction solution was exchanged to a buffer solution containing 25&#x02009;mM NH<sub>4</sub>HCO<sub>3</sub> with 5&#x02009;&#x003bc;g &#x003bc;l<sup>&#x02212;1</sup> trypsin. After 24&#x02009;h incubation at 37&#x02009;&#x000b0;C, the samples (2&#x02009;&#x003bc;g &#x003bc;l<sup>&#x02212;1</sup>) were injected and detected by LC-ESI-MS on an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with EASY-nLC 1200 system (Thermo, San Jose, CA, US) and EASY-spray source (Thermo, San Jose, CA, US). The digestion solution was injected (5&#x02009;&#x003bc;l) at 1&#x02009;&#x003bc;l/min flow rate on to easy column (C18, 0.075&#x02009;mm&#x000d7;150&#x02009;mm, ID 3 &#x003bc;m; Thermo Scientific) Chromatographic separation was using 0.1% formic acid in water as mobile phase A and 0.1% formic acid in 80% acetonitrile as mobile phase B operated at 300&#x02009;nl/min flow rate. Briefly, the gradient employed was 2% buffer B at 2&#x02009;min to 40% buffer B at 40&#x02009;min. Full-scan MS condition: mass range m/z 375-1800 (AGC target 5E5) with lock mass, resolution 60,000 at m/z 200, and maximum injection time of 50&#x02009;ms. Target m/z were isolated for CID with NCE35 and maximum injection time of 100&#x02009;ms. Electrospray voltage was maintained at 1.8&#x02009;kV and capillary temperature was set at 275&#x02009;&#x000b0;C.</p></sec><sec id="Sec13"><title>NMR experiments</title><p id="Par26"><sup>1</sup>H- and <sup>13</sup>C-NMR spectra of compounds <bold>1</bold> and <bold>8</bold> were recorded at 500 and 150&#x02009;MHz, respectively, using a Bruker AMX-500 spectrometer. One- and two- dimensional experiments (correlation spectroscopy (COSY), heteronuclear multi quantum correlation-total correlation spectroscopy (HMQC-TOCSY), and heteronuclear multiple bond correlation (HMBC)) were performed at ambient temperature in D<sub>2</sub>O (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>, <xref rid="MOESM1" ref-type="media">4</xref>; Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">2</xref>). <sup>1</sup>H- (600&#x02009;MHz) and <sup>13</sup>C-NMR (150&#x02009;MHz) spectra of compounds <bold>4,</bold>
<bold>7,</bold>
<bold>9</bold> and <bold>10</bold> were recorded by Bruker Avance 600&#x02009;MHz in D<sub>2</sub>O (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">20</xref>&#x02013;<xref rid="MOESM1" ref-type="media">27</xref>), and their chemical shifts were tabulated in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">5</xref>&#x02013;<xref rid="MOESM1" ref-type="media">8</xref>. The structures of 10- and 12-carbarmoyl <bold>4,</bold>
<bold>9</bold>, and <bold>10</bold> were determined by NMR experiments.</p></sec><sec id="Sec14"><title>Enzyme assay of glycine oxidation</title><p id="Par27">The quantity of glycine oxidation was estimated according to the production of glyoxylate<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Glyoxylate was reacted with 2,4-dinitrophenylhydrazine forming 2,4-dinitrophenylhydrazone derivatives which can be detected at 445&#x02009;nm. The quantity of the derivatives was interpolated against the standard curve of 0.078-1.25&#x02009;mM glyoxylate. The enzyme (20&#x02009;&#x003bc;M) was incubated with addition of 0.2&#x02013;3&#x02009;mM glycine in 100&#x02009;mM sodium phosphate pH 8. The samples (150&#x02009;&#x003bc;l) were withdrawn at 0, 30 and 60&#x02009;seconds and mixed with 75&#x02009;&#x003bc;l 1&#x02009;mM 2,4-dinitrophenylhydrazine in 1&#x02009;M HCl. After 10&#x02009;mins incubation at 37&#x02009;&#x000b0;C, the reactions were added with 525&#x02009;&#x003bc;l 0.6&#x02009;N NaOH for 10&#x02009;mins incubation at room temperature. The absorbance at 445&#x02009;nm was measured by using a DU&#x000ae; 800 UV/Visible spectrophotometer. The relative activity of wild-type and mutants were performed with 20&#x02009;&#x003bc;M enzyme and 2&#x02009;mM glycine in 100&#x02009;mM sodium phosphate pH 8 at 37&#x02009;&#x000b0;C. The data were analyzed by GraphPad Prism using non-linear regression model for fitting the Michaelis-Menten equation.</p></sec><sec id="Sec15"><title>Enzyme Kinetic assay of iminoacetyl-ST-F production</title><p id="Par28">The production quantity of <bold>8</bold> was estimated according to the consumption of <bold>7</bold>. The standard curve was made on the basis of the peak area of 0&#x02013;500&#x02009;&#x003bc;M ST-F at EIC&#x02009;~&#x02009;503.2. Each reaction contained 2.5&#x02009;&#x003bc;M enzyme and 25&#x02013;500&#x02009;&#x003bc;M ST-F in 100&#x02009;mM sodium phosphate pH 8 at 37&#x02009;&#x000b0;C over 10&#x02009;mins. The reactions were quenched by chloroform. After centrifugation, supernatants were injected in to a TSKgel&#x000ae; Amide-80 column (5&#x02009;&#x003bc;m, 4.6&#x02009;mm&#x000d7;250&#x02009;mm) formic acid. mounted on a Water Alliance 2695 HPLC equipped with a Xevo TQ-S micro triple quadrupole mass spectrometer. The gradient employed was 65% (v/v) acetonitrile for 5&#x02009;min and 65&#x02013;20% (v/v) acetonitrile for 25&#x02009;min. Both acetonitrile and water contained 0.1% (v/v) formic acid. The data were analyzed by GraphPad Prism using non-linear regression model for fitting the Michaelis-Menten equation.</p></sec><sec id="Sec16"><title>Measurement of the production of hydrogen peroxide</title><p id="Par29">The hydrogen peroxide production during enzyme reactions was measured using the Pierce<sup>TM</sup> Quantitative Peroxide Assay Kit [<ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/tw/en/23280">https://www.thermofisher.com/order/catalog/product/tw/en/23280</ext-link>]. Each reaction contained 25&#x02009;&#x003bc;M enzyme, 250&#x02009;&#x003bc;M glycine in 100&#x02009;mM sodium phosphate pH 8 buffer at 30&#x02009;&#x000b0;C for 3&#x02009;mins. A sample of 20&#x02009;&#x003bc;l was added with 200&#x02009;&#x003bc;l working reagent at room temperature for 20&#x02009;mins. The absorbance at 595&#x02009;nm was measured using a SpectraMax&#x000ae; M5 microplate reader.</p></sec><sec id="Sec17"><title>Binding affinity determination of Orf1 with ST-F</title><p id="Par30">The binding affinities of ST-F versus Orf1 wild-type or mutants were estimated by using MicroCal iTC200 isothermal titration calorimetry (Malvern Panalytical). The exothermic heat pulse was recorded when 2&#x02009;&#x003bc;l of ST-F (1&#x02013;3&#x02009;mM) was injected to a 200&#x02009;&#x003bc;l protein solution (0.1&#x02009;mM) containing 25&#x02009;mM HEPES pH 7.5 at 25&#x02009;&#x000b0;C. The differential binding curve was fitted with a standard single-site binding model of Origin 7 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">28</xref>).</p></sec><sec id="Sec18"><title>Disc diffusion assay</title><p id="Par31">The <italic>E. coli</italic> strains (BL21 (DE3) and ATCC 25922) were grown at 37&#x02009;&#x000b0;C overnight and spread on the LB agar plate. Five &#x003bc;l of each individual compound (10&#x02009;mM) were loaded onto paper discs and placed on the bacterial lawn of plates. All the plates were incubated overnight at 37&#x02009;&#x000b0;C to observe the zone of inhibition.</p></sec><sec id="Sec19"><title>Reporting summary</title><p id="Par32">Further information on research design is available in the&#x000a0;<xref rid="MOESM3" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec20"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2023_38218_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2023_38218_MOESM2_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2023_38218_MOESM3_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec21"><title>Source data</title><p id="Par36">
<media position="anchor" xlink:href="41467_2023_38218_MOESM4_ESM.xlsx" id="MOESM4"><caption><p>Source data</p></caption></media>
</p></sec></app></app-group><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41467-023-38218-w.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by funds from the Ministry of Science and Technology (MOST), Taiwan (MOST-108-2113-M-001-021-MY3, MOST-110-0210-01-22-02 and MOST-111-2113-M-001-031-MY3) and Academia Sinica (AS-KPQ-109-BioMed, 109-0210-01-18-02 and AS-IA-109-L06). This research was also supported by a JSPS KAKENHI grant for Scientific Research on Innovative Areas 16H06445 (C.M and Y.H), by Grant-in-Aid for Transformative Research Areas 22H05122 (C.M.), and by the JSPS A3 Foresight Program. We thank the experimental facility and the technical services provided by the Synchrotron Radiation Protein Crystallography Core Facility of the National Core Facility for Biopharmaceuticals, Ministry of Science and Technology, and the National Synchrotron Radiation Research Center (NSRRC), a national user facility funded by the Ministry of Science and Technology, Taiwan (R.O.C.). We thank NSRRC for beam time allocations at beam lines TPS-05A, TPS-07A, and TLS-15A. Thank Yi-Chun Liu (NSRRC) for the diffraction-weighted dose estimation. Mass spectrometry analysis were performed by Mass Core Facility of Genomics Research Center, Academia Sinica, Taiwan. We thanked the NMR center of Genomics Research Center for technical support. Thanks also go to Instrumentation Center at NTHU for Bruker ElEXSYS E580 EPR analysis. We thank T. Ito and T. Hibi for discussion on the biochemical analysis of Orf1.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>T.L.L. and Y.H. initiated the study. T.L.L. and Y.H. designed experiments. Y.L.W., C.Y.C. and C.L.C. expressed proteins. Y.L.W. determined protein structures, prepared substrates, designed mutants, and performed enzymatic assays and mass spectrometric analysis. Y.L.W., N.S.H. and K.H.L performed EPR and ITC experiments. I.W.L. and C.F.C performed NMR analysis. Z.C.W. prepared knockout strains. Y.O., T.D., C.M. and Y.H. provided consultations with respect to the BD-12 producing strain and engaged in discussions. T.L.L., Y.H. and Y.W.L. wrote the manuscript.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par33"><italic>Nature Communications</italic> thanks the anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data associated with this study are available within the article, <xref rid="MOESM1" ref-type="media">supplementary information</xref> and Source Data file. The mass spectrometry data have been deposited to the ProteomeXChange Consortium via the PRIDE partner repository with the identifier <ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD041103">PXD041103</ext-link> (username:reviewer_pxd041103@ebi.ac.uk, password:WBKFJVIV), <ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD041104">PXD041104</ext-link> (username:reviewer_pxd041104@ebi.ac.uk, password:ad9bPAJK) and <ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD041105">PXD041105</ext-link> (username:reviewer_pxd041105@ebi.ac.uk, password:3nYMJGKU). All the coordinates and structure factors have been deposited in the Protein Data Bank with accession codes <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XYE/pdb">7XYE</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XQA/pdb">7XQA</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XXD/pdb">7XXD</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XXC/pdb">7XXC</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XXM/pdb">7XXM</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XX0/pdb">7XX0</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XXR/pdb">7XXR</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XYL/pdb">7XYL</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7XXP/pdb">7XXP</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7Y0X/pdb">7Y0X</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb8GRI/pdb">8GRI</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7YPU/pdb">7YPU</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.2210/pdb7YPV/pdb">7YPV</ext-link>.Source data are provided with this paper. All other data are available from the corresponding author on request.&#x000a0;<xref rid="Sec21" ref-type="sec">Source data</xref> are provided with this paper.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waksman</surname><given-names>SA</given-names></name></person-group><article-title>Production and activity of streptothricin</article-title><source>J. Bacteriol.</source><year>1943</year><volume>46</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1128/jb.46.3.299-310.1943</pub-id><?supplied-pmid 16560703?><pub-id pub-id-type="pmid">16560703</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name></person-group><article-title>Two new members of streptothricin class antibiotics from <italic>Streptomyces qinlingensis</italic> sp. nov</article-title><source>J. Antibiot.</source><year>2007</year><volume>60</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1038/ja.2007.96</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borders</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Structures of LL-AC541 and LL-AB664: new streptothricin-type antibiotics</article-title><source>Tetrahedron</source><year>1970</year><volume>26</volume><fpage>3123</fpage><lpage>3133</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(01)92895-9</pub-id><?supplied-pmid 5449036?><pub-id pub-id-type="pmid">5449036</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furumai</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Matsuzawa</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Okuda</surname><given-names>T</given-names></name></person-group><article-title>New basic water-soluble antibiotics BD-12 and BY-81. I. Taxonomy of the producing organisms and antibiotic production</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.283</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><etal/></person-group><article-title>New basic water-soluble antibiotics BD-12 AND BY-81. II. Isolation, purification and properties</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.307</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Glycinothricin, a new streptothricin-class antibiotic from <italic>Streptomyces griseus</italic></article-title><source>J. Antibiot.</source><year>1977</year><volume>30</volume><fpage>460</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.30.460</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>AL</given-names></name><name><surname>McCusker</surname><given-names>JH</given-names></name></person-group><article-title>Three new dominant drug resistance cassettes for gene disruption in <italic>Saccharomyces cerevisiae</italic></article-title><source>Yeast</source><year>1999</year><volume>15</volume><fpage>1541</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0061(199910)15:14&#x0003c;1541::AID-YEA476&#x0003e;3.0.CO;2-K</pub-id><?supplied-pmid 10514571?><pub-id pub-id-type="pmid">10514571</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haupt</surname><given-names>I</given-names></name><name><surname>H&#x000fc;bener</surname><given-names>R</given-names></name><name><surname>Thrum</surname><given-names>H</given-names></name></person-group><article-title>Streptothricin F, an inhibitor of protein synthesis with miscoding activity</article-title><source>J. Antibiot.</source><year>1978</year><volume>31</volume><fpage>1137</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.31.1137</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haupt</surname><given-names>I</given-names></name><name><surname>Jon&#x000e1;k</surname><given-names>J</given-names></name><name><surname>Rychl&#x000ed;k</surname><given-names>I</given-names></name><name><surname>Thrum</surname><given-names>H</given-names></name></person-group><article-title>Action of streptothricin F on ribosomal functions</article-title><source>J. Antibiot.</source><year>1980</year><volume>33</volume><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.33.636</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hentges</surname><given-names>P</given-names></name><name><surname>Van Driessche</surname><given-names>B</given-names></name><name><surname>Tafforeau</surname><given-names>L</given-names></name><name><surname>Vandenhaute</surname><given-names>J</given-names></name><name><surname>Carr</surname><given-names>AM</given-names></name></person-group><article-title>Three novel antibiotic marker cassettes for gene disruption and marker switching in <italic>Schizosaccharomyces pombe</italic></article-title><source>Yeast</source><year>2005</year><volume>22</volume><fpage>1013</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1002/yea.1291</pub-id><?supplied-pmid 16200533?><pub-id pub-id-type="pmid">16200533</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idnurm</surname><given-names>A</given-names></name><name><surname>Reedy</surname><given-names>JL</given-names></name><name><surname>Nussbaum</surname><given-names>JC</given-names></name><name><surname>Heitman</surname><given-names>J</given-names></name></person-group><article-title><italic>Cryptococcus neoformans</italic> virulence gene discovery through insertional mutagenesis</article-title><source>Eukaryot. Cell</source><year>2004</year><volume>3</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1128/EC.3.2.420-429.2004</pub-id><?supplied-pmid 15075272?><pub-id pub-id-type="pmid">15075272</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>PB</given-names></name><name><surname>Webb</surname><given-names>JR</given-names></name><name><surname>Davies</surname><given-names>JE</given-names></name><name><surname>McMaster</surname><given-names>WR</given-names></name></person-group><article-title>The gene encoding streptothricin acetyltransferase (sat) as a selectable marker for <italic>Leishmania</italic> expression vectors</article-title><source>Gene</source><year>1995</year><volume>156</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(95)00042-5</pub-id><?supplied-pmid 7737509?><pub-id pub-id-type="pmid">7737509</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>K&#x000f6;Hler</surname><given-names>JR</given-names></name></person-group><article-title>CaNAT1, a heterologous dominant selectable marker for transformation of <italic>Candida albicans</italic> and other pathogenic <italic>Candida</italic> Species</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.2.1239-1242.2005</pub-id><?supplied-pmid 15664973?><pub-id pub-id-type="pmid">15664973</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Physiological activity of streptothricin antibiotics</article-title><source>Chem. Pharm. Bull.</source><year>1980</year><volume>28</volume><fpage>2884</fpage><lpage>2891</lpage><pub-id pub-id-type="doi">10.1248/cpb.28.2884</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;rtl</surname><given-names>A</given-names></name><name><surname>G&#x000fc;ttner</surname><given-names>J</given-names></name><name><surname>St&#x000f6;ckel</surname><given-names>U</given-names></name><name><surname>Hoffmann</surname><given-names>H</given-names></name></person-group><article-title>Acute and subchronic toxicity of nourseothricin in laboratory animals</article-title><source>Arch. Exp. Veterinarmed.</source><year>1986</year><volume>40</volume><fpage>727</fpage><lpage>735</lpage><?supplied-pmid 3028306?><pub-id pub-id-type="pmid">3028306</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pharmacokinetics of nourseothricin in laboratory animals</article-title><source>Arch. Exp. Veterinarmed.</source><year>1986</year><volume>40</volume><fpage>699</fpage><lpage>709</lpage><?supplied-pmid 3028303?><pub-id pub-id-type="pmid">3028303</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pharmacologic action profile of nourseothricin</article-title><source>Arch. Exp. Veterinarmed.</source><year>1986</year><volume>40</volume><fpage>710</fpage><lpage>720</lpage><?supplied-pmid 3028304?><pub-id pub-id-type="pmid">3028304</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>HJ</given-names></name><name><surname>Graessle</surname><given-names>OE</given-names></name><name><surname>Smith</surname><given-names>DG</given-names></name></person-group><article-title>Studies on the toxicity and activity of streptothricin</article-title><source>Science</source><year>1944</year><volume>99</volume><fpage>540</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1126/science.99.2583.540</pub-id><?supplied-pmid 17755453?><pub-id pub-id-type="pmid">17755453</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamano</surname><given-names>Y</given-names></name><name><surname>Matsuura</surname><given-names>N</given-names></name><name><surname>Kitamura</surname><given-names>M</given-names></name><name><surname>Takagi</surname><given-names>H</given-names></name></person-group><article-title>A novel enzyme conferring streptothricin resistance alters the toxicity of streptothricin D from broad-spectrum to bacteria-specific</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>16842</fpage><lpage>16848</lpage><pub-id pub-id-type="doi">10.1074/jbc.M602294200</pub-id><?supplied-pmid 16641084?><pub-id pub-id-type="pmid">16641084</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Biosynthesis of streptolidine involved two unexpected intermediates produced by a dihydroxylase and a cyclase through unusual mechanisms</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2014</year><volume>53</volume><fpage>1943</fpage><lpage>1948</lpage><pub-id pub-id-type="doi">10.1002/anie.201307989</pub-id><?supplied-pmid 24505011?><pub-id pub-id-type="pmid">24505011</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Biosynthesis of the carbamoylated <sub><italic>D</italic></sub>-gulosamine moiety of streptothricins: involvement of a guanidino-<italic>N</italic>-glycosyltransferase and an <italic>N</italic>-acetyl<italic>-</italic><sub><italic>D</italic></sub>-gulosamine deacetylase</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year><volume>54</volume><fpage>5175</fpage><lpage>5178</lpage><pub-id pub-id-type="doi">10.1002/anie.201412190</pub-id><?supplied-pmid 25728237?><pub-id pub-id-type="pmid">25728237</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>C</given-names></name><etal/></person-group><article-title>A stand-alone adenylation domain forms amide bonds in streptothricin biosynthesis</article-title><source>Nat. Chem. Biol.</source><year>2012</year><volume>8</volume><fpage>791</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1040</pub-id><?supplied-pmid 22820420?><pub-id pub-id-type="pmid">22820420</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>C</given-names></name><name><surname>Hamano</surname><given-names>Y</given-names></name></person-group><article-title>tRNA-dependent amide bond-forming enzymes in peptide natural product biosynthesis</article-title><source>Curr. Opin. Chem. Biol.</source><year>2020</year><volume>59</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2020.08.002</pub-id><?supplied-pmid 32898755?><pub-id pub-id-type="pmid">32898755</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>C</given-names></name><etal/></person-group><article-title>tRNA-dependent aminoacylation of an amino sugar intermediate in the biosynthesis of a streptothricin-related antibiotic</article-title><source>Appl. Environ. Microb.</source><year>2016</year><volume>82</volume><fpage>3640</fpage><lpage>3648</lpage><pub-id pub-id-type="doi">10.1128/AEM.00725-16</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Berkel</surname><given-names>WJH</given-names></name><name><surname>Kamerbeek</surname><given-names>NM</given-names></name><name><surname>Fraaije</surname><given-names>MW</given-names></name></person-group><article-title>Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts</article-title><source>J. Biotechnol.</source><year>2006</year><volume>124</volume><fpage>670</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2006.03.044</pub-id><?supplied-pmid 16712999?><pub-id pub-id-type="pmid">16712999</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>E</given-names></name><name><surname>G&#x000f3;mez Castellanos</surname><given-names>JR</given-names></name><name><surname>Gadda</surname><given-names>G</given-names></name><name><surname>Fraaije</surname><given-names>MW</given-names></name><name><surname>Mattevi</surname><given-names>A</given-names></name></person-group><article-title>Same Substrate, many Reactions: oxygen activation in flavoenzymes</article-title><source>Chem. Rev.</source><year>2018</year><volume>118</volume><fpage>1742</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00650</pub-id><?supplied-pmid 29323892?><pub-id pub-id-type="pmid">29323892</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dairi</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name></person-group><article-title><italic>N</italic>-Formimidoyl fortimicin A synthase, a unique oxidase involved in fortimicin A biosynthesis: purification, characterization and gene cloning</article-title><source>Mol. Gen. Genet.</source><year>1992</year><volume>236</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/BF00279642</pub-id><?supplied-pmid 1494350?><pub-id pub-id-type="pmid">1494350</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>CT</given-names></name></person-group><article-title>Biologically generated carbon dioxide: nature&#x02019;s versatile chemical strategies for carboxy lyases</article-title><source>Nat. Prod. Rep.</source><year>2020</year><volume>37</volume><fpage>100</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1039/C9NP00015A</pub-id><?supplied-pmid 31074473?><pub-id pub-id-type="pmid">31074473</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trisrivirat</surname><given-names>D</given-names></name><name><surname>Sutthaphirom</surname><given-names>C</given-names></name><name><surname>Pimviriyakul</surname><given-names>P</given-names></name><name><surname>Chaiyen</surname><given-names>P</given-names></name></person-group><article-title>Dual activities of oxidation and oxidative decarboxylation by flavoenzymes</article-title><source>Chembiochem</source><year>2022</year><volume>23</volume><fpage>e202100666</fpage><pub-id pub-id-type="doi">10.1002/cbic.202100666</pub-id><?supplied-pmid 35040514?><pub-id pub-id-type="pmid">35040514</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name><name><surname>Pulley</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name></person-group><article-title>Decarboxylation mechanisms in biological system</article-title><source>Bioorg. Chem.</source><year>2012</year><volume>43</volume><fpage>2</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2012.03.001</pub-id><?supplied-pmid 22534166?><pub-id pub-id-type="pmid">22534166</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>KM</given-names></name><name><surname>Serio</surname><given-names>AW</given-names></name><name><surname>Kane</surname><given-names>TR</given-names></name><name><surname>Connolly</surname><given-names>LE</given-names></name></person-group><article-title>Aminoglycosides: an overview</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a027029</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a027029</pub-id><?supplied-pmid 27252397?><pub-id pub-id-type="pmid">27252397</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Horinouchi</surname><given-names>S</given-names></name><name><surname>Uozumi</surname><given-names>T</given-names></name><name><surname>Beppu</surname><given-names>T</given-names></name></person-group><article-title>Purification and biochemical characterization of streptothricin acetyltransferase coded by the cloned streptothricin-resistance gene of <italic>Streptomyces lavendulae</italic></article-title><source>J. Antibiot.</source><year>1987</year><volume>40</volume><fpage>1016</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.40.1016</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Uozumi</surname><given-names>T</given-names></name><name><surname>Beppu</surname><given-names>T</given-names></name></person-group><article-title>Cloning and characterization of the streptothricin-resistance gene which encodes streptothricin acetyltransferase from <italic>Streptomyces lavendulae</italic></article-title><source>J. Antibiot.</source><year>1986</year><volume>39</volume><fpage>688</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.39.688</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Moreno</surname><given-names>MA</given-names></name><name><surname>Vall&#x000ed;n</surname><given-names>C</given-names></name><name><surname>Malpartida</surname><given-names>F</given-names></name></person-group><article-title>Streptothricin biosynthesis is catalyzed by enzymes related to nonribosomal peptide bond formation</article-title><source>J. Bacteriol.</source><year>1997</year><volume>179</volume><fpage>6929</fpage><lpage>6936</lpage><pub-id pub-id-type="doi">10.1128/jb.179.22.6929-6936.1997</pub-id><?supplied-pmid 9371436?><pub-id pub-id-type="pmid">9371436</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000fc;gel</surname><given-names>H</given-names></name><name><surname>Fiedler</surname><given-names>G</given-names></name><name><surname>Haupt</surname><given-names>I</given-names></name><name><surname>Sarfert</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name></person-group><article-title>Analysis of the nourseothricin-resistance Gene (nat.) <italic>Streptomyces noursei</italic>.</article-title><source>Gene</source><year>1988</year><volume>62</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(88)90559-8</pub-id><?supplied-pmid 2835292?><pub-id pub-id-type="pmid">2835292</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahan</surname><given-names>FM</given-names></name><name><surname>Kropp</surname><given-names>H</given-names></name><name><surname>Sundelof</surname><given-names>JG</given-names></name><name><surname>Birnbaum</surname><given-names>J</given-names></name></person-group><article-title>Thienamycin: development of imipenen-cilastatin</article-title><source>J. Antimicrob. Chemother.</source><year>1983</year><volume>12</volume><issue>Suppl D</issue><fpage>1</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/jac/12.suppl_D.1</pub-id><?supplied-pmid 6365872?><pub-id pub-id-type="pmid">6365872</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inouye</surname><given-names>S</given-names></name><name><surname>Niizato</surname><given-names>T</given-names></name><name><surname>Shomura</surname><given-names>T</given-names></name><name><surname>Kitasato</surname><given-names>I</given-names></name></person-group><article-title>Nephrotoxicity of dactimicin, a novel pseudo-disaccharide aminoglycoside possessing the <italic>N</italic>-formimidoyl group, compared with that of astromicin, amikacin and other aminoglycoside antibiotics in animals</article-title><source>Drugs Exp. Clin. Res.</source><year>1989</year><volume>15</volume><fpage>189</fpage><lpage>209</lpage><?supplied-pmid 2791871?><pub-id pub-id-type="pmid">2791871</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>JW</given-names></name><name><surname>Neu</surname><given-names>HC</given-names></name></person-group><article-title>In vitro activity of dactimicin, a novel pseudodisaccharide aminoglycoside, compared with activities of other aminoglycosides</article-title><source>Antimicrob. Agents Chemother.</source><year>1989</year><volume>33</volume><fpage>1998</fpage><lpage>2003</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.11.1998</pub-id><?supplied-pmid 2514625?><pub-id pub-id-type="pmid">2514625</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Formylglycine-generating enzyme binds substrate directly at a mononuclear Cu(I) center to initiate O<sub>2</sub> activation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>5370</fpage><lpage>5375</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818274116</pub-id><?supplied-pmid 30824597?><pub-id pub-id-type="pmid">30824597</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flatt</surname><given-names>PM</given-names></name><name><surname>Mahmud</surname><given-names>T</given-names></name></person-group><article-title>Biosynthesis of aminocyclitol-aminoglycoside antibiotics and related compounds</article-title><source>Nat. Prod. Rep.</source><year>2007</year><volume>24</volume><fpage>358</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1039/B603816F</pub-id><?supplied-pmid 17390001?><pub-id pub-id-type="pmid">17390001</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f6;rtl</surname><given-names>M</given-names></name><etal/></person-group><article-title>Structure-function correlation in glycine oxidase from <italic>Bacillus subtilis</italic></article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>29718</fpage><lpage>29727</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401224200</pub-id><?supplied-pmid 15105420?><pub-id pub-id-type="pmid">15105420</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Settembre</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Structural and mechanistic studies on ThiO, a glycine oxidase essential for thiamin biosynthesis in <italic>Bacillus subtilis</italic></article-title><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>2971</fpage><lpage>2981</lpage><pub-id pub-id-type="doi">10.1021/bi026916v</pub-id><?supplied-pmid 12627963?><pub-id pub-id-type="pmid">12627963</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>L</given-names></name></person-group><article-title>Dali server: structural unification of protein families</article-title><source>Nucleic Acids Res.</source><year>2022</year><volume>50</volume><fpage>W210</fpage><lpage>W215</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac387</pub-id><?supplied-pmid 35610055?><pub-id pub-id-type="pmid">35610055</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname><given-names>E</given-names></name><name><surname>Henrick</surname><given-names>K</given-names></name></person-group><article-title>Inference of macromolecular assemblies from crystalline state</article-title><source>J. Mol. Biol.</source><year>2007</year><volume>372</volume><fpage>774</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.05.022</pub-id><?supplied-pmid 17681537?><pub-id pub-id-type="pmid">17681537</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leys</surname><given-names>D</given-names></name></person-group><article-title>Channelling and formation of &#x02018;active&#x02019; formaldehyde in dimethylglycine oxidase</article-title><source>EMBO J.</source><year>2003</year><volume>22</volume><fpage>4038</fpage><lpage>4048</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg395</pub-id><?supplied-pmid 12912903?><pub-id pub-id-type="pmid">12912903</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umhau</surname><given-names>S</given-names></name><etal/></person-group><article-title>The x-ray structure of <italic>D</italic>-amino acid oxidase at very high resolution identifies the chemical mechanism of flavin-dependent substrate dehydrogenation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>12463</fpage><lpage>12468</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.23.12463</pub-id><?supplied-pmid 11070076?><pub-id pub-id-type="pmid">11070076</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wensien</surname><given-names>M</given-names></name><etal/></person-group><article-title>A lysine&#x02013;cysteine redox switch with an NOS bridge regulates enzyme function</article-title><source>Nature</source><year>2021</year><volume>593</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03513-3</pub-id><?supplied-pmid 33953398?><pub-id pub-id-type="pmid">33953398</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe Von Pappenheim</surname><given-names>F</given-names></name><etal/></person-group><article-title>Widespread occurrence of covalent lysine&#x02013;cysteine redox switches in proteins</article-title><source>Nat. Chem. Biol.</source><year>2022</year><volume>18</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00966-5</pub-id><?supplied-pmid 35165445?><pub-id pub-id-type="pmid">35165445</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H</given-names></name><etal/></person-group><article-title>Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology</article-title><source>Nat. Rev. Mol. Cell Bio.</source><year>2022</year><volume>23</volume><fpage>499</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00456-z</pub-id><pub-id pub-id-type="pmid">35190722</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcock</surname><given-names>LJ</given-names></name><name><surname>Perkins</surname><given-names>MV</given-names></name><name><surname>Chalker</surname><given-names>JM</given-names></name></person-group><article-title>Chemical methods for mapping cysteine oxidation</article-title><source>Chem. Soc. Rev.</source><year>2018</year><volume>47</volume><fpage>231</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1039/C7CS00607A</pub-id><?supplied-pmid 29242887?><pub-id pub-id-type="pmid">29242887</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Carroll</surname><given-names>KS</given-names></name></person-group><article-title>Activity-based sensing for site-specific proteomic analysis of cysteine oxidation</article-title><source>Acc. Chem. Res.</source><year>2020</year><volume>53</volume><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.9b00562</pub-id><?supplied-pmid 31869209?><pub-id pub-id-type="pmid">31869209</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brewer</surname><given-names>TF</given-names></name><name><surname>Garcia</surname><given-names>FJ</given-names></name><name><surname>Onak</surname><given-names>CS</given-names></name><name><surname>Carroll</surname><given-names>KS</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name></person-group><article-title>Chemical approaches to discovery and study of sources and targets of hydrogen peroxide redox signaling through NADPH oxidase proteins</article-title><source>Annu. Rev. Biochem.</source><year>2015</year><volume>84</volume><fpage>765</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060614-034018</pub-id><?supplied-pmid 26034893?><pub-id pub-id-type="pmid">26034893</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chovancova</surname><given-names>E</given-names></name><etal/></person-group><article-title>CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures</article-title><source>PLoS Comput. Biol.</source><year>2012</year><volume>8</volume><fpage>e1002708</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002708</pub-id><?supplied-pmid 23093919?><pub-id pub-id-type="pmid">23093919</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>KA</given-names></name><name><surname>Tattersall</surname><given-names>DB</given-names></name><name><surname>Jones</surname><given-names>PR</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>BL</given-names></name></person-group><article-title>Metabolon formation in dhurrin biosynthesis</article-title><source>Phytochemistry</source><year>2008</year><volume>69</volume><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2007.06.033</pub-id><?supplied-pmid 17706731?><pub-id pub-id-type="pmid">17706731</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sibbesen</surname><given-names>O</given-names></name><name><surname>Koch</surname><given-names>B</given-names></name><name><surname>Halkier</surname><given-names>BA</given-names></name><name><surname>M&#x000f8;Ller</surname><given-names>BL</given-names></name></person-group><article-title>Cytochrome P-450<sub>TYR</sub> is a multifunctional heme-thiolate enzyme catalyzing the conversion of <italic>L</italic>-tyrosine to <italic>p</italic>-hydroxyphenylacetaldehyde oxime in the biosynthesis of the cyanogenic glucoside dhurrin in <italic>Sorghum bicolor</italic> (L.) Moench</article-title><source>J. Biol. Chem.</source><year>1995</year><volume>270</volume><fpage>3506</fpage><lpage>3511</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.8.3506</pub-id><?supplied-pmid 7876084?><pub-id pub-id-type="pmid">7876084</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Toth</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>TM</given-names></name><name><surname>Frase</surname><given-names>H</given-names></name><name><surname>Vakulenko</surname><given-names>SB</given-names></name></person-group><article-title>Structure of the bifunctional aminoglycoside-resistance enzyme AAC(6&#x02019;)-Ie-APH(2&#x0201d;)-Ia revealed by crystallographic and small-angle X-ray scattering analysis</article-title><source>Acta Crystallogr. D. Biol. Crystallogr.</source><year>2014</year><volume>70</volume><fpage>2754</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1107/S1399004714017635</pub-id><?supplied-pmid 25286858?><pub-id pub-id-type="pmid">25286858</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otwinowski</surname><given-names>Z</given-names></name><name><surname>Minor</surname><given-names>W</given-names></name></person-group><article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title><source>Methods Enzymol.</source><year>1997</year><volume>276</volume><fpage>307</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(97)76066-X</pub-id><?supplied-pmid 27754618?><pub-id pub-id-type="pmid">27754618</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bury</surname><given-names>CS</given-names></name><name><surname>Brooks-Bartlett</surname><given-names>JC</given-names></name><name><surname>Walsh</surname><given-names>SP</given-names></name><name><surname>Garman</surname><given-names>EF</given-names></name></person-group><article-title>Estimate your dose: RADDOSE-3D</article-title><source>Protein Sci.</source><year>2018</year><volume>27</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1002/pro.3302</pub-id><?supplied-pmid 28921782?><pub-id pub-id-type="pmid">28921782</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vagin</surname><given-names>A</given-names></name><name><surname>Teplyakov</surname><given-names>A</given-names></name></person-group><article-title>Molecular replacement with MOLREP</article-title><source>Acta Crystallogr. D. Biol. Crystallogr.</source><year>2010</year><volume>66</volume><fpage>22</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042589</pub-id><?supplied-pmid 20057045?><pub-id pub-id-type="pmid">20057045</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaroszewski</surname><given-names>L</given-names></name><name><surname>Rychlewski</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name></person-group><article-title>FFAS03: a server for profile-profile sequence alignments</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><fpage>W284</fpage><lpage>W288</lpage><pub-id pub-id-type="doi">10.1093/nar/gki418</pub-id><?supplied-pmid 15980471?><pub-id pub-id-type="pmid">15980471</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>GN</given-names></name><etal/></person-group><article-title>REFMAC5 for the refinement of macromolecular crystal structures</article-title><source>Acta Crystallogr. D. Biol. Crystallogr.</source><year>2011</year><volume>67</volume><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1107/S0907444911001314</pub-id><?supplied-pmid 21460454?><pub-id pub-id-type="pmid">21460454</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr. D. Biol. Crystallogr.</source><year>2010</year><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><?supplied-pmid 20383002?><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname><given-names>PV</given-names></name><etal/></person-group><article-title>Towards automated crystallographic structure refinement with phenix.refine</article-title><source>Acta Crystallogr. D. Biol. Crystallogr.</source><year>2012</year><volume>68</volume><fpage>352</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1107/S0907444912001308</pub-id><?supplied-pmid 22505256?><pub-id pub-id-type="pmid">22505256</pub-id></element-citation></ref></ref-list></back></article>